BioMarin Pharmaceutical (BMRN) 10-Q 28 Oct 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 18, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Sep-13
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	BMRN
Entity Registrant Name	BIOMARIN PHARMACEUTICAL INC
Entity Central Index Key	1048477
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		142,212,657

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$181,565	$180,527	[1]
Short-term investments	198,086	270,211	[1]
Accounts receivable, net (allowance for doubtful accounts: $376 and $348, respectively)	124,745	109,066	[1]
Inventory	148,684	128,695	[1]
Current deferred tax assets	32,238	29,454	[1]
Other current assets	28,161	25,509	[1]
Total current assets	713,479	743,462	[1]
Noncurrent assets:
Investment in BioMarin/Genzyme LLC	854	1,080	[1]
Long-term investments	147,771	115,993	[1]
Property, plant and equipment, net	285,664	284,473	[1]
Intangible assets, net	165,791	162,980	[1]
Goodwill	54,258	51,543	[1]
Long-term deferred tax assets	238,703	225,501	[1]
Other assets	14,010	16,611	[1]
Total assets	1,620,530	1,601,643	[1]
Current liabilities:
Accounts payable and accrued liabilities	167,633	147,068	[1]
Convertible debt	0	23,365	[1]
Total current liabilities	167,633	170,433	[1]
Noncurrent liabilities:
Long-term convertible debt	78,310	324,859	[1]
Long-term contingent acquisition consideration payable	26,500	30,618	[1]
Long-term deferred tax liabilities	37,190	33,296	[1]
Other long-term liabilities	34,411	26,674	[1]
Total liabilities	344,044	585,880	[1]
Stockholders' equity:
Common stock, $0.001 par value: 250,000,000 shares authorized at September 30, 2013 and December 31, 2012: 142,200,995 and 125,809,162 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively.	142	126	[1]
Additional paid-in capital	1,926,133	1,561,890	[1]
Company common stock held by Nonqualified Deferred Compensation Plan	-7,451	-6,603	[1]
Accumulated other comprehensive income (loss)	11,473	-202	[1]
Accumulated deficit	-653,811	-539,448	[1]
Total stockholders' equity	1,276,486	1,015,763	[1]
Total liabilities and stockholders' equity	$1,620,530	$1,601,643	[1]
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$376	$348	[1]
Common stock, par value	$0.00	$0.00	[1]
Common stock, shares authorized	250,000,000	250,000,000	[1]
Common stock, shares issued	142,200,995	125,809,162	[1]
Common stock, shares outstanding	142,200,995	125,809,162	[1]
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
REVENUES:
Net product revenues	$134,330	$126,310	$394,074	$365,540
Collaborative agreement revenues	1,754	1,210	2,778	1,729
Royalty and license revenues	790	597	4,760	1,516
Total revenues	136,874	128,117	401,612	368,785
OPERATING EXPENSES:
Cost of sales (excludes amortization of certain acquired intangible assets)	28,054	24,619	71,121	65,298
Research and development	88,064	66,209	257,468	217,855
Selling, general and administrative	61,841	46,337	163,547	143,124
Intangible asset amortization and contingent consideration	9,639	1,443	13,173	5,819
Total operating expenses	187,598	138,608	505,309	432,096
LOSS FROM OPERATIONS	-50,724	-10,491	-103,697	-63,311
Equity in the loss of BioMarin/Genzyme LLC	-147	-336	-711	-968
Interest income	574	778	1,942	1,819
Interest expense	-526	-1,837	-2,854	-5,709
Debt conversion expense	-1,732	0	-12,152	0
Other income (expense)	239	125	344	-15
LOSS BEFORE INCOME TAXES	-52,316	-11,761	-117,128	-68,184
Provision for (benefit from) income taxes	704	-6,404	-2,765	-6,849
NET LOSS	-53,020	-5,357	-114,363	-61,335
NET LOSS PER SHARE, BASIC AND DILUTED	($0.38)	($0.04)	($0.84)	($0.52)
Weighted average common shares outstanding, basic and diluted	140,796	123,434	136,102	118,810
COMPREHENSIVE INCOME (LOSS)	($43,988)	($7,674)	($102,688)	($63,889)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($114,363)		($61,335)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	37,880		33,438
Accretion of discount on investments	4,149		3,075
Equity in the loss of BioMarin/Genzyme LLC	711		968
Stock-based compensation	42,638		35,414
Impairment of intangible assets	939		6,707
Deferred income taxes	-19,212		-10,610
Excess tax benefit from stock option exercises	-335		-96
Unrealized foreign exchange loss on forward contracts	-1,692		-4,846
Changes in the fair value of contingent acquisition consideration payable	9,816		-3,325
Debt conversion expense	12,152		0
Changes in operating assets and liabilities:
Accounts receivable, net	-15,679		-12,451
Inventory	-19,989		9,293
Other current assets	-1,776		-8,154
Other assets	-307		-6,905
Accounts payable and accrued liabilities	11,362		15,825
Other long-term liabilities	5,368		8,625
Net cash provided by (used in) operating activities	-48,338		5,623
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	-35,440		-30,676
Maturities and sales of investments	232,625		165,459
Purchase of available-for-sale investments	-179,192		-276,817
Business acquisitions, net of cash acquired	-9,875		0
Investments in BioMarin/Genzyme LLC	-485		-1,258
Net cash provided by (used in) investing activities	7,633		-143,292
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of stock options and ESPP	54,088		37,667
Proceeds from public offering of common stock, net	0		235,499
Excess tax benefit from stock option exercises	335		96
Payments for debt conversion	-12,152		0
Payment on maturity of 2013 convertible note	-98		0
Repayment of capital lease obligations	-430		-535
Net cash provided by financing activities	41,743		272,727
NET INCREASE IN CASH AND CASH EQUIVALENTS	1,038		135,058
Cash and cash equivalents:
Beginning of period	180,527	[1]	46,272
End of period	181,565		181,330
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for interest, net of interest capitalized into fixed assets	3,238		3,597
Cash paid for income taxes	13,165		5,591
Stock-based compensation capitalized into inventory	4,219		3,042
Depreciation capitalized into inventory	8,221		4,744
SUPPLEMENTAL CASH FLOW DISCLOSURES FROM INVESTING AND FINANCING ACTIVITIES:
Decrease in accounts payable and accrued liabilities related to fixed assets	7,491		1,488
Conversion of convertible debt	269,816		0
Deferred offering costs reclassified into additional paid-in-capital as a result of conversion of convertible debt	$2,618		$0
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

NATURE_OF_OPERATIONS_AND_BUSIN

NATURE OF OPERATIONS AND BUSINESS RISKS	9 Months Ended
	Sep. 30, 2013
NATURE OF OPERATIONS AND BUSINESS RISKS	(1) NATURE OF OPERATIONS AND BUSINESS RISKS
	BioMarin Pharmaceutical Inc. (the Company or BioMarin), a Delaware corporation, develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. BioMarin selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s product portfolio is comprised of four approved products and multiple investigational product candidates. The Company’s approved products are Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Firdapse (amifampridine phosphate) and Aldurazyme (laronidase).
	Through September 30, 2013, the Company had accumulated losses of approximately $653.8 million. Management believes that the Company’s cash, cash equivalents, short-term and long-term investments at September 30, 2013 and the proceeds from the convertible notes offering in October 2013 as discussed in Note 20, will be sufficient to meet the Company’s obligations for at least the next twelve months based on management’s current business plans. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital. The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents, short-term and long-term investments, and to the extent necessary, through proceeds from equity or debt financings, loans and collaborative agreements with corporate partners.
	The Company is subject to a number of risks, including: the financial performance of Naglazyme, Kuvan, Firdapse and Aldurazyme; the potential need for additional financings; its ability to successfully commercialize its product candidates, if approved; the uncertainty of the Company’s research and development efforts resulting in future successful commercial products; obtaining regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the health care industry.

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2013
BASIS OF PRESENTATION	(2) BASIS OF PRESENTATION
	The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K.
	The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2013.
	The Company has evaluated events and transactions subsequent to the balance sheet date. Based on this evaluation, the Company is not aware of any events or transactions that occurred subsequent to the balance sheet date but prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements, except for the transaction in Note 20.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2013
SIGNIFICANT ACCOUNTING POLICIES	(3) SIGNIFICANT ACCOUNTING POLICIES
	Except for the clarification of the Company’s inventory policy below, there have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2013, as compared to the significant accounting policies disclosed in Note 3 of the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.
	Inventory
	The Company values inventory at the lower of cost or net realizable value and determines the cost of inventory using the average-cost method. Inventories consist of currently marketed products and may contain certain products awaiting regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.
	The Company analyzes its inventory levels quarterly and writes down inventory that has become obsolete, or has a cost basis in excess of its expected net realizable value and inventory quantities in excess of expected requirements. In applying the lower of cost or net realizable value to pre-launch inventory, the Company estimates a range of likely commercial prices based on its comparable commercial products. Expired inventory is disposed of and the related costs are recognized as Cost of Sales in the Condensed Consolidated Statements of Comprehensive Loss.
	Inventories Produced in Preparation for Product Launches
	The Company capitalizes inventories produced in preparation for product launches sufficient to support estimated initial market demand. Typically, capitalization of such inventory begins when positive results have been obtained for the clinical trials that the Company believes are necessary to support regulatory approval, uncertainties regarding ultimate regulatory approval have been significantly reduced and the Company has determined it is probable that these capitalized costs will provide some future economic benefit in excess of capitalized costs. The material factors considered by the Company in evaluating these uncertainties include the receipt and analysis of positive Phase 3 clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, and the compilation of the regulatory application. The Company closely monitors the status of each respective product within the regulatory approval process, including all relevant communication with regulatory authorities. The Company also considers its historical experience with manufacturing and commercializing similar products and the relevant product candidate. If the Company is aware of any specific material risks or contingencies other than the normal regulatory review and approval process or if there are any specific issues identified relating to safety, efficacy, manufacturing, marketing or labeling, the related inventory would generally not be capitalized.
	For inventories that are capitalized in preparation of product launch, anticipated future sales, expected approval date and shelf lives are evaluated in assessing realizability. The shelf life of a product is determined as part of the regulatory approval process; however in evaluating whether to capitalize pre-launch inventory production costs, the Company considers the product stability data of all of the pre-approval production to date to determine whether there is adequate expected shelf life for the capitalized pre-launch production costs.
	Reclassifications
	Certain items in the Company’s prior year Condensed Consolidated Financial Statements have been reclassified to conform to the current presentation.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2013
RECENT ACCOUNTING PRONOUNCEMENTS	(4) RECENT ACCOUNTING PRONOUNCEMENTS
	Except for Financial Accounting Standards Board (FASB) Accounting Standards Update 2013-02 (ASU 2013-02), Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, there have been no new accounting pronouncements or changes to accounting pronouncements during the period ended September 30, 2013, as compared to the recent accounting pronouncements described in the Company’s Annual Report on Form 10-K for the year-ended December 31, 2012, that are of significance or potential significance to the Company. ASU 2013-02 requires an entity to present either on the face of the financial statements where income is presented or in the notes to the financial statements, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income. See Note 17 to these Condensed Consolidated Financial Statements for the expanded disclosures required by ASU 2013-02.

ACQUISITION_OF_ZACHARON_PHARMA

ACQUISITION OF ZACHARON PHARMACEUTICALS, INC.	9 Months Ended
	Sep. 30, 2013
ACQUISITION OF ZACHARON PHARMACEUTICALS, INC.	(5) ACQUISITION OF ZACHARON PHARMACEUTICALS, INC.
	On January 4, 2013, the Company entered into a merger agreement with Zacharon Pharmaceuticals, Inc. (Zacharon), a private biotechnology company focused on developing small molecules targeting pathways of glycan and glycolipid metabolism for a total purchase price of $11.5 million.
	In connection with its acquisition of Zacharon, the Company made an upfront payment of $9.7 million in cash to the Zacharon stockholders for all of the outstanding common stock of Zacharon, net of transaction costs of $0.8 million paid on behalf of the Zacharon stockholders. The Company also agreed to pay the Zacharon stockholders additional consideration in future periods of up to $134.0 million (undiscounted) in milestone payments if certain clinical, development and sales milestones are met. The fair value of the contingent acquisition consideration payments was $1.9 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. Key assumptions included a discount rate of 4.7% and various probability factors. The range of outcomes and assumptions used to develop these estimates have been updated to estimate the fair value of the contingent consideration payable as of September 30, 2013. See Note 14 to these Condensed Consolidated Financial Statements for additional discussion regarding fair value measurements of the contingent acquisition consideration payable.
	The following table presents the final allocation of the purchase consideration for the Zacharon acquisition, including the contingent acquisition consideration payable, based on fair value. The final allocation includes an adjustment to goodwill and the deferred tax assets of approximately $0.7 million resulting from the finalization of Zacharon’s tax returns.
	Cash and cash equivalents	$	560
	Other current assets		216
	Property, plant and equipment		398
	Acquired deferred tax assets		2,625
	Other assets		38
	Intangible assets—In Process Research & Development (IPR&D)		11,680
	Total identifiable assets acquired	$	15,517
	Accounts payable and accrued expenses	$	(1,182	)
	Debt assumed		(1,313	)
	Deferred tax liability		(4,217	)
	Total liabilities assumed	$	(6,712	)
	Net identifiable assets acquired	$	8,805
	Goodwill		2,715
	Net assets acquired	$	11,520
	A substantial portion of the assets acquired consisted of intangible assets related to Zacharon’s SENSI-Pro assay. The Company determined that the estimated acquisition-date fair value of the intangible assets related to the SENSI-Pro assay was $11.7 million.
	The $2.6 million of deferred tax assets resulting from the acquisition was primarily related to federal and state net operating loss and tax credit carryforwards. The $4.2 million of deferred tax liabilities relates to the tax impact of future amortization or possible impairments associated with the identified intangible assets acquired, which are not deductible for tax purposes.
	The excess of the consideration transferred over the fair values assigned to the assets acquired and liabilities assumed was $2.7 million, which represents the amount of goodwill resulting from the acquisition. The Company believes that the goodwill primarily represents synergies expected from the acquisition and other benefits that do not qualify for separate recognition as acquired intangible assets. None of the goodwill is expected to be deductible for income tax purposes. The Company recorded the goodwill in the Company’s Condensed Consolidated Balance Sheet as of the acquisition date.
	Zacharon’s results of operations prior to and since the acquisition date are insignificant to the Company’s Condensed Consolidated Financial Statements.
	See Note 8 to these Condensed Consolidated Financial Statements for further discussion of the acquired intangible assets.

INVESTMENTS

INVESTMENTS	9 Months Ended
	Sep. 30, 2013
INVESTMENTS	(6) INVESTMENTS
	All investments were classified as available-for-sale at September 30, 2013 and December 31, 2012.
	The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale securities by major security type at September 30, 2013 were as follows:
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Holding Gains		Holding Losses
	Certificates of deposit	$	45,530	$	3	$	0		$	45,533
	Corporate debt securities		218,767		231		(256	)		218,742
	Corporate equity securities		3,000		17,333		0			20,333
	Commercial paper		52,182		38		0			52,220
	U.S. Government agency securities		8,900		1		0			8,901
	Greek government-issued bonds		51		77		0			128
	Total	$	328,430	$	17,683	$	(256	)	$	345,857
	The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale securities by major security type at December 31, 2012 were as follows:
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Holding Gains		Holding Losses
	Certificates of deposit	$	48,741	$	14	$	(1	)	$	48,754
	Corporate debt securities		316,709		402		(211	)		316,900
	Corporate equity securities		3,000		0		(67	)		2,933
	U.S. Government agency securities		17,512		5		0			17,517
	Greek government-issued bonds		48		52		0			100
	Total	$	386,010	$	473	$	(279	)	$	386,204
	The fair values of available-for-sale securities by contractual maturity at September 30, 2013 and December 31, 2012 were as follows:
		September 30,		December 31,
		2013		2012
	Maturing in one year or less	$	198,086	$	270,211
	Maturing after one year through two years		147,771		115,993
	Total	$	345,857	$	386,204
	Impairment assessments are made at the individual security level each reporting period. When the fair value of an investment is less than its cost at the balance sheet date, a determination is made as to whether the impairment is other-than-temporary and, if it is other-than-temporary, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date. As of September 30, 2013, some of the Company’s investments were in an unrealized loss position. However, none of the underlying investments has been in a continuous loss position longer than twelve months, and no other-than-temporary impairment is deemed to have occurred.
	See Note 14 to these Condensed Consolidated Financial Statements for additional discussion regarding the fair value of the Company’s available-for-sale securities.

GOODWILL

GOODWILL	9 Months Ended
	Sep. 30, 2013
GOODWILL	(7) GOODWILL
	Goodwill is tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in the circumstances that would indicate a reduction in the fair value of the goodwill below its carrying amount.
	The following table represents the changes in goodwill for the nine months ended September 30, 2013:
	Balance at December 31, 2012	$	51,543
	Addition of goodwill related to the acquisition of Zacharon		2,715
	Balance at September 30, 2013	$	54,258

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2013
INTANGIBLE ASSETS	(8) INTANGIBLE ASSETS
	Intangible assets consisted of the following:
		September 30,			December 31,
		2013			2012
	Intangible assets:
	Finite-lived intangible assets	$	118,242		$	118,242
	Indefinite-lived intangible assets		74,430			63,689
	Gross intangible assets:		192,672			181,931
	Less: Accumulated amortization		(26,881	)		(18,951	)
	Net carrying value	$	165,791		$	162,980
	Indefinite-Lived Intangible Assets
	Indefinite-lived intangible assets consist of IPR&D assets related to both early and late stage product candidates purchased in the acquisitions of Huxley Pharmaceuticals Inc. (Huxley), LEAD Therapeutics, Inc. (LEAD), ZyStor Therapeutics, Inc. (ZyStor) and Zacharon.
	Intangible assets related to IPR&D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D assets below their respective carrying amounts.
	See Note 6 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, for additional information related to the Company’s intangible assets.

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	9 Months Ended
	Sep. 30, 2013
PROPERTY, PLANT AND EQUIPMENT	(9) PROPERTY, PLANT AND EQUIPMENT
	Property, plant and equipment, net consisted of the following:
		September 30,			December 31,
		2013			2012
	Leasehold improvements	$	67,083		$	65,918
	Building and improvements		154,479			144,700
	Manufacturing and laboratory equipment		88,865			79,915
	Computer hardware and software		63,164			56,011
	Furniture and equipment		12,152			11,143
	Land		11,608			11,608
	Construction-in-progress		64,756			64,300
			462,107			433,595
	Less: Accumulated depreciation		(176,443	)		(149,122	)
	Total property, plant and equipment, net	$	285,664		$	284,473
	Depreciation expense for the three and nine months ended September 30, 2013 was $9.2 million and $27.3 million, respectively, of which $2.8 million and $8.2 million was capitalized into inventory, respectively. Depreciation expense for the three and nine months ended September 30, 2012 was $8.9 million and $25.7 million, respectively, of which $2.5 million and $4.7 million was capitalized into inventory, respectively.
	Capitalized interest related to the Company’s property, plant and equipment purchases for the three and nine months ended September 30, 2013 and 2012 was insignificant.

INVENTORY

INVENTORY	9 Months Ended
	Sep. 30, 2013
INVENTORY	(10) INVENTORY
	Inventory consisted of the following:
		September 30,		December 31,
		2013		2012
	Raw materials	$	15,350	$	11,943
	Work-in-process		80,996		71,443
	Finished goods		52,338		45,309
	Total inventory	$	148,684	$	128,695
	Inventory as of September 30, 2013 and December 31, 2012 included $32.7 million and $0, respectively, of Vimizim raw materials and work-in-progress related to the pre-launch Vimizim manufacturing campaign. The Company believes that all material uncertainties related to the ultimate regulatory approval of Vimizim for commercial sale have been significantly reduced based on positive data from Phase 3 clinical trial results, successful pre-filing meetings with the Food and Drug Administration (FDA) for the Biologics License Application (BLA), the filing of the BLA with the FDA in the first quarter of 2013, and the filing of the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) in April 2013. In its evaluation, the Company also considered its historical experience with developing and commercially producing similar products.
	Inventory as of September 30, 2013 and December 31, 2012 also included $2.2 million and $12.0 million, respectively, of product manufactured using certain process and specification changes that have not yet received regulatory approval. Although a product may have been approved by a regulatory agency, the process and specification changes must also be approved before product produced with the alternate processes and specifications can be sold commercially.
	The Company expects to receive regulatory approval and has determined that it is probable that the Company will realize the future economic benefit associated with the costs of these inventories through future sales.

SUPPLEMENTAL_BALANCE_SHEET_INF

SUPPLEMENTAL BALANCE SHEET INFORMATION	9 Months Ended
	Sep. 30, 2013
SUPPLEMENTAL BALANCE SHEET INFORMATION	(11) SUPPLEMENTAL BALANCE SHEET INFORMATION
	Accounts payable and accrued liabilities consisted of the following:
		September 30,		December 31,
		2013		2012
	Accounts payable	$	15,632	$	23,993
	Accrued accounts payable		58,666		43,156
	Accrued vacation expense		9,717		8,403
	Accrued compensation expense		28,574		27,530
	Accrued royalties payable		5,279		4,991
	Accrued rebates payable		10,147		9,625
	Other accrued operating expenses		1,891		6,179
	Current portion of nonqualified deferred compensation liability		1,559		6,440
	Value added taxes payable		4,240		2,072
	Current portion of contingent acquisition consideration payable		26,536		10,764
	Other		5,392		3,915
	Total accounts payable and accrued liabilities	$	167,633	$	147,068

DERIVATIVE_INSTRUMENTS_AND_HED

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES	9 Months Ended
	Sep. 30, 2013
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES	(12) DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
	Foreign Currency Exchange Rate Exposure
	The Company uses forward foreign currency exchange contracts to hedge certain operational exposures resulting from changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted revenues and operating expenses being denominated in currencies other than the U.S. dollar, primarily the Euro and Brazilian Real, respectively.
	The Company designates certain of these forward foreign currency exchange contracts as hedging instruments and enters into some forward foreign currency exchange contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward foreign currency exchange contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from Naglazyme product revenues, Aldurazyme royalty revenues, operating expenses and net asset or liability positions designated in currencies other than the U.S. dollar. The fair values of forward foreign currency exchange contracts are estimated using current exchange rates and interest rates, and take into consideration the current creditworthiness of the counterparties or the Company, as applicable. Details of the specific instruments used by the Company to hedge its exposure to foreign currency exchange rate fluctuations are discussed below. See Note 14 to these Condensed Consolidated Financial Statements for additional discussion regarding the fair value of forward foreign currency exchange contracts.
	At September 30, 2013, the Company had 58 forward foreign currency exchange contracts outstanding to sell a total of 57.1 million Euros with expiration dates ranging from October 31, 2013 through December 31, 2014. These hedges were entered into in order to protect against the fluctuations in revenue associated with Euro denominated Naglazyme and Aldurazyme sales. The Company has formally designated these forward foreign currency exchange contracts as cash flow hedges and expects them to be highly effective within the meaning of FASB Accounting Standards Codification (ASC) Subtopic 815-30, Derivatives and Hedging-Cash Flow Hedges, in offsetting fluctuations in revenues denominated in Euros and operating expenses denominated in the Brazilian Real related to changes in foreign currency exchange rates.
	The Company also enters into forward foreign currency exchange contracts that are not designated as hedges for accounting purposes. The changes in fair value of these forward foreign currency exchange contracts are included as a part of Selling, General and Administrative expense in the Condensed Consolidated Statements of Comprehensive Loss. At September 30, 2013, separate from the 58 contracts discussed above, the Company had one outstanding forward foreign currency exchange contract to sell 28.1 million Euros, which was not designated as a hedge for accounting purposes and which will mature on October 31, 2013.
	The maximum length of time over which the Company is hedging its exposure to the reduction in value of forecasted foreign currency cash flows through forward foreign currency exchange contracts is through December 31, 2014. Over the next twelve months, the Company expects to reclassify $2.0 million from accumulated other comprehensive income to earnings as the forecasted revenue transactions and operating expenses occur.
	The fair value carrying amounts of the Company’s derivative instruments were as follows:
			Asset Derivatives						Liability Derivatives
			September 30, 2013						September 30, 2013
			Balance Sheet Location			Fair Value			Balance Sheet Location			Fair Value
	Derivatives designated as hedging instruments:
	Forward foreign currency exchange contracts			Other current assets		$	0			Accounts payable and		$	1,674
										accrued liabilities
	Forward foreign currency exchange contracts			Other assets			0			Other long-			131
										term liabilities
	Total					$	0					$	1,805
	Derivatives not designated as hedging instruments:
	Forward foreign currency exchange contracts			Other current assets		$	0			Accounts payable and		$	146
										accrued liabilities
	Total						0						146
	Total value of derivative contracts					$	0					$	1,951
			Asset Derivatives						Liability Derivatives
			December 31, 2012						December 31, 2012
			Balance Sheet Location			Fair Value			Balance Sheet Location			Fair Value
	Derivatives designated as hedging instruments:
	Forward foreign currency exchange contracts			Other current assets		$	1,463			Accounts payable and		$	1,078
										accrued liabilities
	Forward foreign currency exchange contracts			Other assets			0			Other long-			368
										term liabilities
	Total					$	1,463					$	1,446
	Derivatives not designated as hedging instruments:
	Forward foreign currency exchange contracts			Other current assets		$	84			Accounts payable and		$	0
										accrued liabilities
	Total						84						0
	Total value of derivative contracts					$	1,547					$	1,446
	The effect of the Company’s derivative instruments on the Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2013 and 2012 was as follows:
			Forward Foreign Currency Exchange Contracts
			Three Months Ended September 30,						Nine Months Ended September 30,
			2013			2012			2013			2012
	Derivatives Designated as Hedging Instruments:
	Net gain (loss) recognized in Other Comprehensive Income (OCI) (1)		$	(3,177	)	$	(3,952	)	$	(1,918	)	$	(4,612	)
	Net gain reclassified from accumulated OCI into income (2)			102			2,362			968			4,916
	Net gain recognized in income (3)			10			218			214			753
	Derivatives Not Designated as Hedging Instruments:
	Net gain (loss) recognized in income (4)		$	(1,437	)	$	(1,388	)	$	(1,129	)	$	1,286
	-1	Net change in the fair value of the effective portion classified as OCI.
	-2	Effective portion classified as net product revenue.
	-3	Ineffective portion and amount excluded from effectiveness testing classified as selling, general and administrative expense.
	-4	Classified as selling, general and administrative expense.
	At September 30, 2013 and December 31, 2012, accumulated other comprehensive income before taxes associated with forward foreign currency exchange contracts qualifying for hedge accounting treatment were losses of $2.1 million and $0.2 million, respectively.
	The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintained strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.

CONVERTIBLE_DEBT

CONVERTIBLE DEBT	9 Months Ended
	Sep. 30, 2013
CONVERTIBLE DEBT	(13) CONVERTIBLE DEBT
	In April 2007, the Company sold approximately $324.9 million of senior subordinated convertible notes due in April 2017 (the 2017 Notes), of which $78.3 million remains outstanding at September 30, 2013. The debt was issued at face value and bears interest at the rate of 1.875% per annum, payable semi-annually in cash. The debt is convertible, at the option of the holder, at any time prior to maturity or redemption, into shares of the Company’s common stock at a conversion price of approximately $20.36 per share, subject to adjustment in certain circumstances. The debt does not include a call provision and the Company is unable to unilaterally redeem the debt prior to maturity on April 23, 2017. The Company also must repay the debt if there is a qualifying change in control or termination of trading of its common stock. If a change of control occurs, the Company will pay a make whole premium by increasing the conversion rate applicable to the notes.
	In connection with the placement of the 2017 Notes, the Company paid approximately $8.5 million in offering costs, which have been deferred and are included in other assets. The deferred offering costs are being amortized as interest expense over the life of the debt. The Company recognized amortization expense of $0.1 million and $0.3 million for the three and nine months ended September 30, 2013, compared to $0.2 million and $0.6 million for the three and nine months ended September 30, 2012, respectively.
	In August 2013, the Company entered into separate agreements with three of the existing holders of its 2017 Notes pursuant to which such holders converted $31.5 million in aggregate principal amount of the 2017 Notes into 1,547,629 shares of the Company’s common stock. In addition to issuing the requisite number of shares of the Company’s common stock pursuant to the 2017 Notes, the Company also made varying cash payments to each of the holders, totaling $1.9 million in the aggregate, of which $1.7 million was recognized in total as Debt Conversion Expense on the Condensed Consolidated Statement of Comprehensive Loss for the three and nine months ended September 30, 2013 and $0.2 million was for accrued interest. Additionally, the Company reclassified $0.3 million of deferred offering costs to additional paid-in capital in connection with the conversion of the 2017 Notes.
	In March 2013, the Company entered into separate agreements with 13 of the existing holders of its 2017 Notes pursuant to which such holders converted $215.0 million in aggregate principal amount of the 2017 Notes into 10,560,164 shares of the Company’s common stock. In addition to issuing the requisite number of shares of the Company’s common stock pursuant to the 2017 Notes, the Company also made varying cash payments to each of the holders, totaling $12.0 million in the aggregate, of which $10.4 million was recognized in total as Debt Conversion Expense on the Condensed Consolidated Statement of Comprehensive Loss for the nine months ended September 30, 2013 and $1.6 million was for accrued interest. Additionally, the Company reclassified $2.3 million of deferred offering costs to additional paid-in capital in connection with the conversion of the 2017 Notes.
	In March 2006, the Company sold $172.5 million of senior subordinated convertible notes due in March 2013 (the 2013 Notes), which fully matured on March 29, 2013. The debt was issued at face value and bore interest at the rate of 2.5% per annum, payable semi-annually in cash. The debt was convertible, at the option of the holder, at any time prior to maturity or redemption, into shares of the Company’s common stock at a conversion price of approximately $16.58 per share, subject to adjustment in certain circumstances. The debt did not include a call provision and the Company was unable to unilaterally redeem the debt prior to maturity on March 29, 2013. Upon maturity of the remaining convertible notes outstanding in March 2013, the Company issued the requisite 1,403,735 shares of common stock pursuant to the 2013 Notes to the bond holders, in exchange for $23.3 million in aggregate principal and paid one bond holder the par value at maturity in cash totaling $98.
	The Company’s total fixed rate convertible debt outstanding was as follows:
		September 30, 2013		December 31, 2012
	Fixed rate convertible debt on balance sheet	$	78,310	$	348,224
	Fair value of fixed rate convertible debt	$	280,387	$	811,798
	The fair value of the Company’s fixed rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy.
	Interest expense on the Company’s convertible debt for the three and nine months ended September 30, 2013 was $0.5 million and $2.5 million, respectively, compared to $1.7 million and $5.0 million for the three months and nine months ended September 30, 2012, respectively.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2013
FAIR VALUE MEASUREMENTS	(14) FAIR VALUE MEASUREMENTS
	The Company measures certain financial assets and liabilities at fair value on a recurring basis, including available-for-sale fixed income securities and foreign currency derivatives. The tables below present the fair value of these financial assets and liabilities determined using the following input levels.
			Fair Value Measurements at September 30, 2013
			Quoted Price in			Significant Other		Significant		Total
			Active  Markets			Observable Inputs		Unobservable
			for Identical			(Level 2)		Inputs
			Assets					(Level 3)
			(Level  1)
	Assets:
	Cash and cash equivalents:
	Overnight deposits		$	170,717		$	0	$	0	$	170,717
	Money market instruments			0			10,848		0		10,848
	Total cash and cash equivalents		$	170,717		$	10,848	$	0	$	181,565
	Available-for-sale securities:
	Short-term:
	Certificates of deposit		$	0		$	31,061	$	0	$	31,061
	Corporate debt securities			0			94,472		0		94,472
	Corporate equity securities			0			20,333		0		20,333
	Commercial paper			0			52,220		0		52,220
	Long-term:
	Certificates of deposit			0			14,472		0		14,472
	Corporate debt securities			0			124,270		0		124,270
	U.S. Government agency securities			0			8,901		0		8,901
	Greek government-issued bonds			0			128		0		128
	Total available-for-sale securities		$	0		$	345,857	$	0	$	345,857
	Other Current Assets:
	Nonqualified Deferred Compensation Plan assets		$	0		$	49	$	0	$	49
	Restricted investments (2)			0			2,528		0		2,528
	Total other current assets		$	0		$	2,577	$	0	$	2,577
	Other Assets:
	Nonqualified Deferred Compensation Plan assets		$	0		$	3,350	$	0	$	3,350
	Restricted investments (2)			0			1,489		0		1,489
	Total other assets		$	0		$	4,839	$	0	$	4,839
	Total assets		$	170,171		$	364,121	$	0	$	534,838
	Liabilities:
	Current Liabilities:
	Nonqualified Deferred Compensation Plan liability		$	1,510		$	49	$	0	$	1,559
	Forward foreign currency exchange contract liability (1)			0			1,820		0		1,820
	Contingent acquisition consideration payable			0			0		26,536		26,536
	Total current liabilities		$	1,510		$	1,869	$	26,536	$	29,915
	Other long-term liabilities:
	Nonqualified Deferred Compensation Plan liability		$	12,468		$	3,350	$	0	$	15,818
	Forward foreign currency exchange contract liability (1)			0			131		0		131
	Contingent acquisition consideration payable			0			0		26,500		26,500
	Asset retirement obligation			0			0		4,014		4,014
	Total other long-term liabilities		$	12,468		$	3,481	$	30,514	$	46,463
	Total liabilities		$	13,978		$	5,350	$	57,050	$	76,378
			Fair Value Measurements at December 31, 2012
			Quoted Price in			Significant Other		Significant		Total
			Active Markets			Observable Inputs		Unobservable
			for Identical			(Level 2)		Inputs
			Assets					(Level 3)
			(Level  1)
	Assets:
	Cash and cash equivalents:
	Overnight deposits		$	54,018		$	0	$	0	$	54,018
	Money market instruments			0			126,509		0		126,509
	Total cash and cash equivalents		$	54,018		$	126,509	$	0	$	180,527
	Available-for-sale securities:
	Short-term:
	Certificates of deposit		$	0		$	36,615	$	0	$	36,615
	Corporate debt securities			0			222,147		0		222,147
	Corporate equity securities			0			2,933		0		2,933
	U.S. Government agency securities			0			8,516		0		8,516
Long-term:
Certificates of deposit			0			12,139		0		12,139
Corporate debt securities			0			94,753		0		94,753
U.S. Government agency securities			0			9,001		0		9,001
Greek government-issued bonds			0			100		0		100
Total available-for-sale securities		$	0		$	386,204	$	0	$	386,204
Other Current Assets:
Nonqualified Deferred Compensation Plan assets		$	0		$	2,052	$	0	$	2,052
Forward foreign currency exchange contract asset (1)			0			1,547		0		1,547
Restricted investments (2)			0			2,243		0		2,243
Total other current assets		$	0		$	5,842	$	0	$	5,842
Other Assets:
Nonqualified Deferred Compensation Plan assets		$	0		$	2,375	$	0	$	2,375
Restricted investments (2)			0			3,492		0		3,492
Total other assets		$	0		$	5,867	$	0	$	5,867
Total assets		$	54,018		$	524,422	$	0	$	578,440
Liabilities:
Current Liabilities:
Nonqualified Deferred Compensation Plan liability		$	6,440		$	0	$	0	$	6,440
Forward foreign currency exchange contract liability (1)			0			1,078		0		1,078
Contingent acquisition consideration payable			0			0		10,764		10,764
Asset retirement obligation			0			0		1,685		1,685
Total current liabilities		$	6,440		$	1,078	$	12,449	$	19,967
Other long-term liabilities:
Nonqualified Deferred Compensation Plan liability		$	5,041		$	4,427	$	0	$	9,468
Forward foreign currency exchange contract liability (1)			0			368		0		368
Contingent acquisition consideration payable			0			0		30,618		30,618
Asset retirement obligation			0			0		2,192		2,192
Total other long-term liabilities		$	5,041		$	4,795	$	32,810	$	42,646
Total liabilities		$	11,481		$	5,873	$	45,259	$	62,613
-1	See Note 12 to these Condensed Consolidated Financial Statements for further information regarding the derivative instruments.
-2	The restricted investments secure the Company’s irrevocable standby letter of credit obtained in connection with the Company’s new corporate facility lease agreements and certain commercial agreements.
There were no transfers between levels during the three and nine months ended September 30, 2013.
The Company’s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.
The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets. Due to the continued volatility associated with market conditions in Greece and reduced trading activity in its sovereign debt, the Company classified its Greek government-issued bonds as Level 2 on September 30, 2013 and December 31 2012. See Note 6 to these Condensed Consolidated Financial Statements for further information regarding the Company’s financial instruments.
Liabilities measured at fair value using Level 3 inputs were comprised of contingent acquisition consideration payable and asset retirement obligations.
The Company’s contingent acquisition consideration payable is estimated using a probability-based income approach utilizing an appropriate discount rate. Key assumptions used by management to estimate the fair value of contingent acquisition consideration payable include estimated probabilities, the estimated timing of when a milestone may be attained and assumed discount periods and rates. Subsequent changes in the fair value of the contingent acquisition consideration payable, resulting from management’s revision of key assumptions, will be recorded in Intangible Asset Amortization and Contingent Consideration on the Condensed Consolidated Statements of Comprehensive Loss.
Contingent acquisition consideration payable at December 31, 2012		$	41,382
Changes in the fair value of the contingent acquisition consideration payable			9,816
Addition of contingent consideration payable related to the Zacharon acquisition			1,857
Milestone payment to former LEAD shareholders			(19	)
Contingent acquisition consideration payable at September 30, 2013		$	53,036
Under certain of the Company’s lease agreements, the Company is contractually obligated to return leased space to its original condition upon termination of the lease agreement. The Company records an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation when estimable. In subsequent periods, for each such lease, the Company records interest expense to accrete the asset retirement obligation liability to full value and depreciates each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. The Company’s asset retirement obligations were $4.0 million at September 30, 2013 and $3.9 million at December 31, 2012.
The Company acquired intangible assets as a result of various business acquisitions. The estimated fair value of these long-lived assets was measured using Level 3 inputs as of the acquisition date.

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2013
STOCK-BASED COMPENSATION	(15) STOCK-BASED COMPENSATION
	On May 8, 2012, the Company’s Board of Directors approved the BioMarin Pharmaceutical Inc. 2012 Inducement Plan (the 2012 Inducement Plan), which provided for grants of up to 750,000 share-based awards to new employees including grants of restricted stock units and grants of options to purchase common stock at a price equal to the fair market value of such shares. The awards granted under the 2012 Inducement Plan are substantially similar to those granted under the Company’s 2006 Share Incentive Plan as amended and restated on March 22, 2010 and as further amended on May 15, 2013 (the 2006 Share Incentive Plan). The 2012 Inducement Plan expired in May 2013 and no further awards will be made under the plan.
	In addition to the 2012 Inducement Plan, the Company’s stock-based compensation plans include the 2006 Share Incentive Plan and the Employee Stock Purchase Plan (the ESPP). The Company’s stock-based compensation plans are administered by the Compensation Committee of the Board of Directors, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the award. See Note 13 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, for additional information related to these stock-based compensation plans.
	Determining the Fair Value of Stock Options and Stock Purchase Rights
	The fair value of each option award is estimated on the date of grant using the Black-Scholes valuation model and the assumptions noted in the tables below. The expected life of options is based on observed historical exercise patterns. Groups of employees that have similar historical exercise patterns were considered separately for valuation purposes, but none were identified that had distinctly different exercise patterns as of September 30, 2013. The expected volatility of stock options is based upon the weighted average of the historical volatility of the Company’s common stock and the implied volatility of traded options on the Company’s common stock for fiscal periods in which there is sufficient trading volume in options on the Company’s common stock. The risk-free interest rate is based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term equal to the expected term of the option. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. The assumptions used to estimate the per share fair value of stock options granted under the 2012 Inducement Plan and the 2006 Share Incentive Plan were as follows:
		Three Months Ended September 30,			Nine Months Ended September 30,
		2013		2012	2013		2012
	Expected volatility	44%		46%	44 – 45%		45 – 46%
	Dividend yield	0.00%		0.00%	0.00%		0.00%
	Expected life	6.8 years		6.5 years	6.6-6.8 years		6.5 years
	Risk-free interest rate	2.20%		0.90%	1.0 – 2.4%		0.8 – 1.1%
	During the nine months ended September 30, 2013, the Company granted 2,403,722 million options with a weighted average option value of $30.62 per option.
	The Company did not grant any new stock purchase rights under the ESPP during the three months ended September 30, 2013.
	Restricted Stock Unit Awards with Service-Based Vesting Conditions
	Restricted stock units (RSUs) are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. During the nine months ended September 30, 2013, the Company granted 558,231 RSUs with a weighted average fair market value of $66.74 per share.
	Restricted Stock Unit Awards with Performance and Market-Based Vesting Conditions
	Pursuant to the approval of the Board of Directors, the Company granted RSU awards with performance and market-based vesting conditions during 2012 and 2011 to certain executive officers. As of September 30, 2013, these awards provide for a base award of 860,000 RSUs (Base RSUs), with a weighted-average grant date fair value of $34.66. The number of RSUs that could potentially vest from the Base RSUs granted is contingent upon achievement of specific performance goals and will be multiplied by the Total Shareholder Return multiplier which could range from 75% to 125% to determine the number of earned RSUs.
	Stock-based compensation expense for this award will be recognized over the remaining service period beginning in the period the Company determines that achievement of strategic performance goal or goals is probable. Accordingly, because the Company’s management has not determined that the achievement of the goals is probable as of September 30, 2013, no compensation expense has been recognized for these awards for the three and nine months ended September 30, 2013 and 2012.
	Compensation expense included in the Condensed Consolidated Statements of Comprehensive Loss for all stock-based compensation arrangements was as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013		2012
	Cost of sales	$	1,489		$	1,327		$	3,663	$	3,535
	Research and development		7,116			5,060			18,821		15,351
	Selling, general and administrative		7,600			5,752			19,214		17,021
	Total stock-based compensation expense	$	16,205		$	12,139		$	41,698	$	35,907
	Stock-based compensation of $4.2 million and $3.0 million was capitalized into inventory for the nine months ended September 30, 2013 and 2012, respectively. Capitalized stock-based compensation is recognized as cost of sales when the related product is sold.

NET_LOSS_PER_COMMON_SHARE

NET LOSS PER COMMON SHARE	9 Months Ended
	Sep. 30, 2013
NET LOSS PER COMMON SHARE	(16) NET LOSS PER COMMON SHARE
	Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the ESPP, unvested restricted stock, common stock held by the Company’s Nonqualified Deferred Compensation Plan and contingent issuances of common stock related to convertible debt. The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method (in thousands):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Options to purchase common stock		13,421		15,998		13,421		15,998
	Common stock issuable under convertible debt		3,846		17,370		3,846		17,370
	Unvested restricted stock units		1,235		1,297		1,180		1,256
	Potentially issuable common stock for ESPP purchases		290		263		282		254
	Common stock held by the Nonqualified Deferred Compensation Plan		194		233		194		233
	Total number of potentially issuable shares		18,986		35,161		18,923		35,111
	See Note 20 to these Condensed Consolidated Financial Statements for additional discussion regarding potential common shares outstanding at September 30, 2013 had the issuance of the Company’s Senior Subordinated Convertible Notes due in October 2018 and 2020 occurred on or before September 30, 2013.

COMPREHENSIVE_INCOME

COMPREHENSIVE INCOME	9 Months Ended
	Sep. 30, 2013
COMPREHENSIVE INCOME	(17) COMPREHENSIVE INCOME
	The following table summarizes amounts reclassified out of Accumulated Other Comprehensive Income/(Loss) (AOCI) and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2013.
		Amount Reclassified from  AOCI
		(Gain)/Loss
	Details about AOCI Components	Three Months			Nine Months			Condensed Consolidated Statement of
		Ended			Ended			Comprehensive Loss Classification
		September 30, 2013			September 30, 2013
	Gains on cash flow hedges:
	Forward foreign currency exchange contracts	$	(101	)	$	(928	)	Net product revenues
	Forward foreign currency exchange contracts		0			(40	)	Selling, general and administrative
			36			349		Provision for income taxes
		$	(65	)	$	(619	)	Net loss
	The following table summarizes changes in the accumulated balances for each component, of other comprehensive income/(loss), including current period other comprehensive income and reclassifications act of AOCI, for the nine months ended September 30, 2013.
		Gains/(Losses)			Unrealized			Foreign			Total
		on Cash  Flow			Gain/(Losses)  on			Currency
		Hedges			Available-for-sale			Translation
					Securities			Adjustments
	AOCI balance, net of tax at December 31, 2012	$	(97	)	$	133		$	(238	)	$	(202	)
	Other comprehensive income before reclassifications		(606	)		11,007			1,893			12,294
	Amounts reclassified from AOCI		(619	)		0			0			(619	)
	Net increase in other comprehensive income (loss)		(1,225	)		11,007			1,893			11,675
	AOCI balance, net of tax at September 30, 2013	$	(1,322	)	$	11,140		$	1,655		$	11,473

REVENUE_AND_CREDIT_CONCENTRATI

REVENUE AND CREDIT CONCENTRATIONS	9 Months Ended
	Sep. 30, 2013
REVENUE AND CREDIT CONCENTRATIONS	(18) REVENUE AND CREDIT CONCENTRATIONS
	Net Product Revenue—The Company considers there to be revenue concentration risks for regions where net product revenue exceeds ten percent of consolidated net product revenue. The concentration of the Company’s net product revenue within the regions below may have a material adverse effect on the Company’s revenue and results of operations if sales in the respective regions experience difficulties.
	The table below summarizes net product revenue concentrations based on patient location for Naglazyme, Kuvan and Firdapse and Genzyme’s headquarters for Aldurazyme. Although Genzyme sells Aldurazyme worldwide, the royalties earned by the Company on Genzyme’s net sales are included in the U.S. region, as the transactions are with Genzyme whose headquarters are located in the U.S.
			Three Months Ended September 30,						Nine Months Ended September 30,
			2013			2012			2013			2012
	Region:
	United States			54	%		53	%		51	%		50	%
	Europe			21	%		21	%		21	%		22	%
	Latin America			8	%		14	%		12	%		15	%
	Rest of world			17	%		12	%		16	%		13	%
	Total net product revenue			100	%		100	%		100	%		100	%
	The following table illustrates the percentage of the consolidated net product revenue attributed to the Company’s four largest customers.
			Three Months Ended September 30,			Nine Months Ended September 30,
			2013		2012	2013		2012
	Customer A		15%		14%	15%		15%
	Customer B (1)		17%		18%	15%		15%
	Customer C		4%		11%	8%		12%
	Customer D		11%		9%	11%		9%
	Total		47%		52%	49%		51%
	-1	Genzyme is the Company’s sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third-parties. Net product revenues from Genzyme are comprised of royalties on worldwide net Aldurazyme sales and incremental product transfer revenue.
	The accounts receivable balances at September 30, 2013 and December 31, 2012 were comprised of amounts due from customers for net product sales of Naglazyme, Kuvan and Firdapse and Aldurazyme product transfer and royalty revenues. On a consolidated basis, the Company’s two largest customers accounted for 39% and 13% of the September 30, 2013 accounts receivable balance, respectively, compared to December 31, 2012 when the two largest customers accounted for 51% and 13% of the accounts receivable balance, respectively. As of September 30, 2013 and December 31, 2012, accounts receivable for the Company’s largest customer balance included $28.2 million and $32.4 million, respectively, of unbilled accounts receivable related to net incremental Aldurazyme product transfers to Genzyme. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires immediate payment in certain circumstances.
	The Company’s product sales to government-owned or government-funded customers in certain European countries, including Italy, Spain, Portugal and Greece, are subject to payment terms that are statutorily determined. Because these customers are government-owned or government-funded, the Company may be impacted by declines in sovereign credit ratings or sovereign defaults in these countries. A significant or further decline in sovereign credit ratings or a default in these countries may decrease the likelihood that the Company will collect accounts receivable or may increase the discount rates and the length of time until receivables are collected, which could result in a negative impact to the Company’s operating results. In both the three and nine months ended September 30, 2013, approximately 4% of the Company’s net product revenues were from these countries. Additionally, approximately 12% of the Company’s outstanding accounts receivable at September 30, 2013 related to such countries.
	The following table summarizes the accounts receivable by country that were past due related to Italy, Spain, Portugal and Greece, the number of days past due and the total allowance for doubtful accounts related to each of these countries at September 30, 2013.
			Days Past Due
			< 180 Days			180  —360			> 360 Days			Total Amount			Allowance for
						Days						Past  Due			Doubtful  Accounts
	Italy		$	0		$	0		$	0		$	0		$	0
	Spain			1,920			1,467			1,216			4,603			0
	Portugal			267			0			0			267			0
	Greece			0			0			359			359			359
	Total		$	2,187		$	1,467		$	1,575		$	5,229		$	359
	The Company has not historically experienced a significant level of uncollected receivables and has received continued payments from its more aged accounts. The Company believes that the allowances for doubtful accounts related to these countries is adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2013
COMMITMENTS AND CONTINGENCIES	(19) COMMITMENTS AND CONTINGENCIES
	The Company is also subject to contingent payments totaling approximately $438.4 million as of September 30, 2013, which are due upon achievement of certain regulatory and licensing milestones if they occur before certain dates in the future. Of this amount, $57.6 million relates to programs that are no longer being developed.

SUBSEQUENT_EVENT

SUBSEQUENT EVENT	9 Months Ended
	Sep. 30, 2013
SUBSEQUENT EVENT	(20) SUBSEQUENT EVENT
	On October 15, 2013, the Company completed an offering of $750.0 million in aggregate principal of senior subordinated convertible notes consisting of $375.0 million 0.75% Senior Subordinated Convertible Notes due in October 2018 (the 2018 Notes) and $375.0 million 1.50% Senior Subordinated Convertible Notes due in October 2020 (the 2020 Notes and collectively the Notes). The net proceeds from the offering were approximately $726.4 million, after deducting commissions and estimated offering expenses payable by the Company. The 2018 Notes and the 2020 Notes accrue interest at annual rates of 0.75% and 1.50%, respectively, with interest payable semiannually in arrears on April 15 and October 15 of each year beginning on April 15, 2014. The Notes are convertible, under certain circumstances, into cash, shares of the Company’s common stock or a combination at the Company’s election. The initial conversion rate is 10.6213 shares of common stock per $1,000 principal amount of Notes, representing the initial conversion price of approximately $94.15 per common share.
	Concurrent with the issuance of the Notes, the Company used approximately $29.8 million of proceeds to enter into privately-negotiated capped call transactions with respect to 50% of the principal amount of the 2018 Notes and 50% of the principal amount of the 2020 Notes with certain of the underwriters of the Notes or their affiliates. The capped call transactions are generally expected to reduce potential dilution of the Company’s common stock upon conversion of the relevant Notes in excess of the principal amount of the Notes. The capped call transactions have a cap price of approximately $121.05, subject to certain adjustments under the terms of the capped call transactions.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2013
Inventory	Inventory
	The Company values inventory at the lower of cost or net realizable value and determines the cost of inventory using the average-cost method. Inventories consist of currently marketed products and may contain certain products awaiting regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.
	The Company analyzes its inventory levels quarterly and writes down inventory that has become obsolete, or has a cost basis in excess of its expected net realizable value and inventory quantities in excess of expected requirements. In applying the lower of cost or net realizable value to pre-launch inventory, the Company estimates a range of likely commercial prices based on its comparable commercial products. Expired inventory is disposed of and the related costs are recognized as Cost of Sales in the Condensed Consolidated Statements of Comprehensive Loss.
Reclassifications	Reclassifications
	Certain items in the Company’s prior year Condensed Consolidated Financial Statements have been reclassified to conform to the current presentation.
Prior to Regulatory Approval
Inventory	Inventories Produced in Preparation for Product Launches
	The Company capitalizes inventories produced in preparation for product launches sufficient to support estimated initial market demand. Typically, capitalization of such inventory begins when positive results have been obtained for the clinical trials that the Company believes are necessary to support regulatory approval, uncertainties regarding ultimate regulatory approval have been significantly reduced and the Company has determined it is probable that these capitalized costs will provide some future economic benefit in excess of capitalized costs. The material factors considered by the Company in evaluating these uncertainties include the receipt and analysis of positive Phase 3 clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, and the compilation of the regulatory application. The Company closely monitors the status of each respective product within the regulatory approval process, including all relevant communication with regulatory authorities. The Company also considers its historical experience with manufacturing and commercializing similar products and the relevant product candidate. If the Company is aware of any specific material risks or contingencies other than the normal regulatory review and approval process or if there are any specific issues identified relating to safety, efficacy, manufacturing, marketing or labeling, the related inventory would generally not be capitalized.
	For inventories that are capitalized in preparation of product launch, anticipated future sales, expected approval date and shelf lives are evaluated in assessing realizability. The shelf life of a product is determined as part of the regulatory approval process; however in evaluating whether to capitalize pre-launch inventory production costs, the Company considers the product stability data of all of the pre-approval production to date to determine whether there is adequate expected shelf life for the capitalized pre-launch production costs.

ACQUISITION_OF_ZACHARON_PHARMA1

ACQUISITION OF ZACHARON PHARMACEUTICALS, INC. (Tables) (Zacharon Pharmaceuticals Inc)	9 Months Ended
	Sep. 30, 2013
Zacharon Pharmaceuticals Inc
Schedule of Purchase Price Allocation	The following table presents the final allocation of the purchase consideration for the Zacharon acquisition, including the contingent acquisition consideration payable, based on fair value. The final allocation includes an adjustment to goodwill and the deferred tax assets of approximately $0.7 million resulting from the finalization of Zacharon’s tax returns.
	Cash and cash equivalents	$	560
	Other current assets		216
	Property, plant and equipment		398
	Acquired deferred tax assets		2,625
	Other assets		38
	Intangible assets—In Process Research & Development (IPR&D)		11,680
	Total identifiable assets acquired	$	15,517
	Accounts payable and accrued expenses	$	(1,182	)
	Debt assumed		(1,313	)
	Deferred tax liability		(4,217	)
	Total liabilities assumed	$	(6,712	)
	Net identifiable assets acquired	$	8,805
	Goodwill		2,715
	Net assets acquired	$	11,520

INVESTMENTS_Tables

INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2013
Amortized Cost, Gross Unrealized Holding Gain or Loss, and Fair Value of Available For Sale Security by Major Security type	The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale securities by major security type at September 30, 2013 were as follows:
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Holding Gains		Holding Losses
	Certificates of deposit	$	45,530	$	3	$	0		$	45,533
	Corporate debt securities		218,767		231		(256	)		218,742
	Corporate equity securities		3,000		17,333		0			20,333
	Commercial paper		52,182		38		0			52,220
	U.S. Government agency securities		8,900		1		0			8,901
	Greek government-issued bonds		51		77		0			128
	Total	$	328,430	$	17,683	$	(256	)	$	345,857
	The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale securities by major security type at December 31, 2012 were as follows:
		Amortized		Gross		Gross			Fair Value
		Cost		Unrealized		Unrealized
				Holding Gains		Holding Losses
	Certificates of deposit	$	48,741	$	14	$	(1	)	$	48,754
	Corporate debt securities		316,709		402		(211	)		316,900
	Corporate equity securities		3,000		0		(67	)		2,933
	U.S. Government agency securities		17,512		5		0			17,517
	Greek government-issued bonds		48		52		0			100
	Total	$	386,010	$	473	$	(279	)	$	386,204
Fair Values of Available-For-Sale Securities by Contractual Maturity	The fair values of available-for-sale securities by contractual maturity at September 30, 2013 and December 31, 2012 were as follows:
		September 30,		December 31,
		2013		2012
	Maturing in one year or less	$	198,086	$	270,211
	Maturing after one year through two years		147,771		115,993
	Total	$	345,857	$	386,204

GOODWILL_Tables

GOODWILL (Tables)	9 Months Ended
	Sep. 30, 2013
Changes in Goodwill	The following table represents the changes in goodwill for the nine months ended September 30, 2013:
	Balance at December 31, 2012	$	51,543
	Addition of goodwill related to the acquisition of Zacharon		2,715
	Balance at September 30, 2013	$	54,258

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Intangible Assets	Intangible assets consisted of the following:
		September 30,			December 31,
		2013			2012
	Intangible assets:
	Finite-lived intangible assets	$	118,242		$	118,242
	Indefinite-lived intangible assets		74,430			63,689
	Gross intangible assets:		192,672			181,931
	Less: Accumulated amortization		(26,881	)		(18,951	)
	Net carrying value	$	165,791		$	162,980

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Property Plant and Equipment Net	Property, plant and equipment, net consisted of the following:
		September 30,			December 31,
		2013			2012
	Leasehold improvements	$	67,083		$	65,918
	Building and improvements		154,479			144,700
	Manufacturing and laboratory equipment		88,865			79,915
	Computer hardware and software		63,164			56,011
	Furniture and equipment		12,152			11,143
	Land		11,608			11,608
	Construction-in-progress		64,756			64,300
			462,107			433,595
	Less: Accumulated depreciation		(176,443	)		(149,122	)
	Total property, plant and equipment, net	$	285,664		$	284,473

INVENTORY_Tables

INVENTORY (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Inventory	Inventory consisted of the following:
		September 30,		December 31,
		2013		2012
	Raw materials	$	15,350	$	11,943
	Work-in-process		80,996		71,443
	Finished goods		52,338		45,309
	Total inventory	$	148,684	$	128,695

SUPPLEMENTAL_BALANCE_SHEET_INF1

SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Accounts Payable and Accrued Liabilities	Accounts payable and accrued liabilities consisted of the following:
		September 30,		December 31,
		2013		2012
	Accounts payable	$	15,632	$	23,993
	Accrued accounts payable		58,666		43,156
	Accrued vacation expense		9,717		8,403
	Accrued compensation expense		28,574		27,530
	Accrued royalties payable		5,279		4,991
	Accrued rebates payable		10,147		9,625
	Other accrued operating expenses		1,891		6,179
	Current portion of nonqualified deferred compensation liability		1,559		6,440
	Value added taxes payable		4,240		2,072
	Current portion of contingent acquisition consideration payable		26,536		10,764
	Other		5,392		3,915
	Total accounts payable and accrued liabilities	$	167,633	$	147,068

DERIVATIVE_INSTRUMENTS_AND_HED1

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Carrying Amount of Derivative Instruments	The fair value carrying amounts of the Company’s derivative instruments were as follows:
			Asset Derivatives						Liability Derivatives
			September 30, 2013						September 30, 2013
			Balance Sheet Location			Fair Value			Balance Sheet Location			Fair Value
	Derivatives designated as hedging instruments:
	Forward foreign currency exchange contracts			Other current assets		$	0			Accounts payable and		$	1,674
										accrued liabilities
	Forward foreign currency exchange contracts			Other assets			0			Other long-			131
										term liabilities
	Total					$	0					$	1,805
	Derivatives not designated as hedging instruments:
	Forward foreign currency exchange contracts			Other current assets		$	0			Accounts payable and		$	146
										accrued liabilities
	Total						0						146
	Total value of derivative contracts					$	0					$	1,951
			Asset Derivatives						Liability Derivatives
			December 31, 2012						December 31, 2012
			Balance Sheet Location			Fair Value			Balance Sheet Location			Fair Value
	Derivatives designated as hedging instruments:
	Forward foreign currency exchange contracts			Other current assets		$	1,463			Accounts payable and		$	1,078
										accrued liabilities
	Forward foreign currency exchange contracts			Other assets			0			Other long-			368
										term liabilities
	Total					$	1,463					$	1,446
	Derivatives not designated as hedging instruments:
	Forward foreign currency exchange contracts			Other current assets		$	84			Accounts payable and		$	0
										accrued liabilities
	Total						84						0
	Total value of derivative contracts					$	1,547					$	1,446
Effect of Derivative Instruments	The effect of the Company’s derivative instruments on the Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2013 and 2012 was as follows:
			Forward Foreign Currency Exchange Contracts
			Three Months Ended September 30,						Nine Months Ended September 30,
			2013			2012			2013			2012
	Derivatives Designated as Hedging Instruments:
	Net gain (loss) recognized in Other Comprehensive Income (OCI) (1)		$	(3,177	)	$	(3,952	)	$	(1,918	)	$	(4,612	)
	Net gain reclassified from accumulated OCI into income (2)			102			2,362			968			4,916
	Net gain recognized in income (3)			10			218			214			753
	Derivatives Not Designated as Hedging Instruments:
	Net gain (loss) recognized in income (4)		$	(1,437	)	$	(1,388	)	$	(1,129	)	$	1,286
	-1	Net change in the fair value of the effective portion classified as OCI.
	-2	Effective portion classified as net product revenue.
	-3	Ineffective portion and amount excluded from effectiveness testing classified as selling, general and administrative expense.
	-4	Classified as selling, general and administrative expense.

CONVERTIBLE_DEBT_Tables

CONVERTIBLE DEBT (Tables)	9 Months Ended
	Sep. 30, 2013
Fixed Rate Convertible Debt Outstanding	The Company’s total fixed rate convertible debt outstanding was as follows:
		September 30, 2013		December 31, 2012
	Fixed rate convertible debt on balance sheet	$	78,310	$	348,224
	Fair value of fixed rate convertible debt	$	280,387	$	811,798

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value of Financial Assets and Liabilities	The tables below present the fair value of these financial assets and liabilities determined using the following input levels.
			Fair Value Measurements at September 30, 2013
			Quoted Price in			Significant Other		Significant		Total
			Active  Markets			Observable Inputs		Unobservable
			for Identical			(Level 2)		Inputs
			Assets					(Level 3)
			(Level  1)
	Assets:
	Cash and cash equivalents:
	Overnight deposits		$	170,717		$	0	$	0	$	170,717
	Money market instruments			0			10,848		0		10,848
	Total cash and cash equivalents		$	170,717		$	10,848	$	0	$	181,565
	Available-for-sale securities:
	Short-term:
	Certificates of deposit		$	0		$	31,061	$	0	$	31,061
	Corporate debt securities			0			94,472		0		94,472
	Corporate equity securities			0			20,333		0		20,333
	Commercial paper			0			52,220		0		52,220
	Long-term:
	Certificates of deposit			0			14,472		0		14,472
	Corporate debt securities			0			124,270		0		124,270
	U.S. Government agency securities			0			8,901		0		8,901
	Greek government-issued bonds			0			128		0		128
	Total available-for-sale securities		$	0		$	345,857	$	0	$	345,857
	Other Current Assets:
	Nonqualified Deferred Compensation Plan assets		$	0		$	49	$	0	$	49
	Restricted investments (2)			0			2,528		0		2,528
	Total other current assets		$	0		$	2,577	$	0	$	2,577
	Other Assets:
	Nonqualified Deferred Compensation Plan assets		$	0		$	3,350	$	0	$	3,350
	Restricted investments (2)			0			1,489		0		1,489
	Total other assets		$	0		$	4,839	$	0	$	4,839
	Total assets		$	170,171		$	364,121	$	0	$	534,838
	Liabilities:
	Current Liabilities:
	Nonqualified Deferred Compensation Plan liability		$	1,510		$	49	$	0	$	1,559
	Forward foreign currency exchange contract liability (1)			0			1,820		0		1,820
	Contingent acquisition consideration payable			0			0		26,536		26,536
	Total current liabilities		$	1,510		$	1,869	$	26,536	$	29,915
	Other long-term liabilities:
	Nonqualified Deferred Compensation Plan liability		$	12,468		$	3,350	$	0	$	15,818
	Forward foreign currency exchange contract liability (1)			0			131		0		131
	Contingent acquisition consideration payable			0			0		26,500		26,500
	Asset retirement obligation			0			0		4,014		4,014
	Total other long-term liabilities		$	12,468		$	3,481	$	30,514	$	46,463
	Total liabilities		$	13,978		$	5,350	$	57,050	$	76,378
			Fair Value Measurements at December 31, 2012
			Quoted Price in			Significant Other		Significant		Total
			Active Markets			Observable Inputs		Unobservable
			for Identical			(Level 2)		Inputs
			Assets					(Level 3)
			(Level  1)
	Assets:
	Cash and cash equivalents:
	Overnight deposits		$	54,018		$	0	$	0	$	54,018
	Money market instruments			0			126,509		0		126,509
	Total cash and cash equivalents		$	54,018		$	126,509	$	0	$	180,527
	Available-for-sale securities:
	Short-term:
	Certificates of deposit		$	0		$	36,615	$	0	$	36,615
	Corporate debt securities			0			222,147		0		222,147
	Corporate equity securities			0			2,933		0		2,933
	U.S. Government agency securities			0			8,516		0		8,516
	Long-term:
Certificates of deposit			0			12,139		0		12,139
Corporate debt securities			0			94,753		0		94,753
U.S. Government agency securities			0			9,001		0		9,001
Greek government-issued bonds			0			100		0		100
Total available-for-sale securities		$	0		$	386,204	$	0	$	386,204
Other Current Assets:
Nonqualified Deferred Compensation Plan assets		$	0		$	2,052	$	0	$	2,052
Forward foreign currency exchange contract asset (1)			0			1,547		0		1,547
Restricted investments (2)			0			2,243		0		2,243
Total other current assets		$	0		$	5,842	$	0	$	5,842
Other Assets:
Nonqualified Deferred Compensation Plan assets		$	0		$	2,375	$	0	$	2,375
Restricted investments (2)			0			3,492		0		3,492
Total other assets		$	0		$	5,867	$	0	$	5,867
Total assets		$	54,018		$	524,422	$	0	$	578,440
Liabilities:
Current Liabilities:
Nonqualified Deferred Compensation Plan liability		$	6,440		$	0	$	0	$	6,440
Forward foreign currency exchange contract liability (1)			0			1,078		0		1,078
Contingent acquisition consideration payable			0			0		10,764		10,764
Asset retirement obligation			0			0		1,685		1,685
Total current liabilities		$	6,440		$	1,078	$	12,449	$	19,967
Other long-term liabilities:
Nonqualified Deferred Compensation Plan liability		$	5,041		$	4,427	$	0	$	9,468
Forward foreign currency exchange contract liability (1)			0			368		0		368
Contingent acquisition consideration payable			0			0		30,618		30,618
Asset retirement obligation			0			0		2,192		2,192
Total other long-term liabilities		$	5,041		$	4,795	$	32,810	$	42,646
Total liabilities		$	11,481		$	5,873	$	45,259	$	62,613
-1	See Note 12 to these Condensed Consolidated Financial Statements for further information regarding the derivative instruments.
-2	The restricted investments secure the Company’s irrevocable standby letter of credit obtained in connection with the Company’s new corporate facility lease agreements and certain commercial agreements.
Liabilities Measured at Fair Value Using Level 3 Inputs
	Contingent acquisition consideration payable at December 31, 2012		$	41,382
	Changes in the fair value of the contingent acquisition consideration payable			9,816
	Addition of contingent consideration payable related to the Zacharon acquisition			1,857
	Milestone payment to former LEAD shareholders			(19	)
	Contingent acquisition consideration payable at September 30, 2013		$	53,036

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2013
Stock Option Valuation Assumptions	The assumptions used to estimate the per share fair value of stock options granted under the 2012 Inducement Plan and the 2006 Share Incentive Plan were as follows:
		Three Months Ended September 30,			Nine Months Ended September 30,
		2013		2012	2013		2012
	Expected volatility	44%		46%	44 – 45%		45 – 46%
	Dividend yield	0.00%		0.00%	0.00%		0.00%
	Expected life	6.8 years		6.5 years	6.6-6.8 years		6.5 years
	Risk-free interest rate	2.20%		0.90%	1.0 – 2.4%		0.8 – 1.1%
Stock-Based Compensation Expense	Compensation expense included in the Condensed Consolidated Statements of Comprehensive Loss for all stock-based compensation arrangements was as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013		2012
	Cost of sales	$	1,489		$	1,327		$	3,663	$	3,535
	Research and development		7,116			5,060			18,821		15,351
	Selling, general and administrative		7,600			5,752			19,214		17,021
	Total stock-based compensation expense	$	16,205		$	12,139		$	41,698	$	35,907

NET_LOSS_PER_COMMON_SHARE_Tabl

NET LOSS PER COMMON SHARE (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share	The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method (in thousands):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Options to purchase common stock		13,421		15,998		13,421		15,998
	Common stock issuable under convertible debt		3,846		17,370		3,846		17,370
	Unvested restricted stock units		1,235		1,297		1,180		1,256
	Potentially issuable common stock for ESPP purchases		290		263		282		254
	Common stock held by the Nonqualified Deferred Compensation Plan		194		233		194		233
	Total number of potentially issuable shares		18,986		35,161		18,923		35,111

COMPREHENSIVE_INCOME_Tables

COMPREHENSIVE INCOME (Tables)	9 Months Ended
	Sep. 30, 2013
Amounts Reclassified out of Accumulated Other Comprehensive Income or Loss	The following table summarizes amounts reclassified out of Accumulated Other Comprehensive Income/(Loss) (AOCI) and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2013.
		Amount Reclassified from  AOCI
		(Gain)/Loss
	Details about AOCI Components	Three Months			Nine Months			Condensed Consolidated Statement of
		Ended			Ended			Comprehensive Loss Classification
		September 30, 2013			September 30, 2013
	Gains on cash flow hedges:
	Forward foreign currency exchange contracts	$	(101	)	$	(928	)	Net product revenues
	Forward foreign currency exchange contracts		0			(40	)	Selling, general and administrative
			36			349		Provision for income taxes
		$	(65	)	$	(619	)	Net loss
Summary of Changes in Accumulated Balances of Other Comprehensive Income Loss Including Current Period Other Comprehensive Income and Reclassifications	The following table summarizes changes in the accumulated balances for each component, of other comprehensive income/(loss), including current period other comprehensive income and reclassifications act of AOCI, for the nine months ended September 30, 2013.
		Gains/(Losses)			Unrealized			Foreign			Total
		on Cash  Flow			Gain/(Losses)  on			Currency
		Hedges			Available-for-sale			Translation
					Securities			Adjustments
	AOCI balance, net of tax at December 31, 2012	$	(97	)	$	133		$	(238	)	$	(202	)
	Other comprehensive income before reclassifications		(606	)		11,007			1,893			12,294
	Amounts reclassified from AOCI		(619	)		0			0			(619	)
	Net increase in other comprehensive income (loss)		(1,225	)		11,007			1,893			11,675
	AOCI balance, net of tax at September 30, 2013	$	(1,322	)	$	11,140		$	1,655		$	11,473

REVENUE_AND_CREDIT_CONCENTRATI1

REVENUE AND CREDIT CONCENTRATIONS (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule Of Accounts Receivable by Country that were Past Due	The following table summarizes the accounts receivable by country that were past due related to Italy, Spain, Portugal and Greece, the number of days past due and the total allowance for doubtful accounts related to each of these countries at September 30, 2013.
			Days Past Due
			< 180 Days			180  —360			> 360 Days			Total Amount			Allowance for
						Days						Past  Due			Doubtful  Accounts
	Italy		$	0		$	0		$	0		$	0		$	0
	Spain			1,920			1,467			1,216			4,603			0
	Portugal			267			0			0			267			0
	Greece			0			0			359			359			359
	Total		$	2,187		$	1,467		$	1,575		$	5,229		$	359
Geographic Concentration Risk | Net Product Revenues
Schedules of Net Product Revenue Concentration	The table below summarizes net product revenue concentrations based on patient location for Naglazyme, Kuvan and Firdapse and Genzyme’s headquarters for Aldurazyme. Although Genzyme sells Aldurazyme worldwide, the royalties earned by the Company on Genzyme’s net sales are included in the U.S. region, as the transactions are with Genzyme whose headquarters are located in the U.S.
			Three Months Ended September 30,						Nine Months Ended September 30,
			2013			2012			2013			2012
	Region:
	United States			54	%		53	%		51	%		50	%
	Europe			21	%		21	%		21	%		22	%
	Latin America			8	%		14	%		12	%		15	%
	Rest of world			17	%		12	%		16	%		13	%
	Total net product revenue			100	%		100	%		100	%		100	%
Customer Concentration Risk | Net Product Revenues
Schedules of Net Product Revenue Concentration	The following table illustrates the percentage of the consolidated net product revenue attributed to the Company’s four largest customers.
			Three Months Ended September 30,			Nine Months Ended September 30,
			2013		2012	2013		2012
	Customer A		15%		14%	15%		15%
	Customer B (1)		17%		18%	15%		15%
	Customer C		4%		11%	8%		12%
	Customer D		11%		9%	11%		9%
	Total		47%		52%	49%		51%
	-1	Genzyme is the Company’s sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third-parties. Net product revenues from Genzyme are comprised of royalties on worldwide net Aldurazyme sales and incremental product transfer revenue.

Recovered_Sheet1

Nature of Operations and Business Risks - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Nature Of Operations [Line Items]
Accumulated losses	($653,811)	($539,448)	[1]
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

Recovered_Sheet2

Acquisition of Zacharon Pharmaceuticals Incorporated - Additional Information (Detail) (Zacharon Pharmaceuticals Inc, USD $)	0 Months Ended	9 Months Ended
	Jan. 04, 2013	Sep. 30, 2013
Zacharon Pharmaceuticals Inc
Business Acquisition [Line Items]
Total purchase price	$11,500,000
Acquisition cash paid, net of transaction costs	9,700,000
Acquisition-related transaction costs	800,000
Maximum potential additional consideration milestone payments	134,000,000
Fair value of intangible assets	1,900,000
Discount rate		4.70%
Adjustment to goodwill and deferred tax assets		700,000
Intangible assets	11,680,000
Deferred tax assets acquisition	2,625,000
Deferred tax liability	4,217,000
Goodwill resulting from acquisition	$2,700,000

Allocation_of_Purchase_Conside

Allocation of Purchase Consideration Including Contingent Acquisition Consideration Payable (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012		Jan. 04, 2013
In Thousands, unless otherwise specified				Zacharon Pharmaceuticals Inc
Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]
Cash and cash equivalents				$560
Other current assets				216
Property, plant and equipment				398
Acquired deferred tax assets				2,625
Other assets				38
Intangible assets-In Process Research & Development (IPR&D)				11,680
Total identifiable assets acquired				15,517
Accounts payable and accrued expenses				-1,182
Debt assumed				-1,313
Deferred tax liability				-4,217
Total liabilities assumed				-6,712
Net identifiable assets acquired				8,805
Goodwill	54,258	51,543	[1]	2,715
Net assets acquired				$11,520
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

Amortized_Cost_Gross_Unrealize

Amortized Cost Gross Unrealized Holding Gain or Loss and Fair Value of Available for Sale Security by Major Security Type (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$328,430	$386,010
Gross Unrealized Holding Gains	17,683	473
Gross Unrealized Holding Losses	-256	-279
Fair Value	345,857	386,204
Certificates of Deposit
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	45,530	48,741
Gross Unrealized Holding Gains	3	14
Gross Unrealized Holding Losses	0	-1
Fair Value	45,533	48,754
Corporate Debt Securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	218,767	316,709
Gross Unrealized Holding Gains	231	402
Gross Unrealized Holding Losses	-256	-211
Fair Value	218,742	316,900
Corporate Equity Securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	3,000	3,000
Gross Unrealized Holding Gains	17,333	0
Gross Unrealized Holding Losses	0	-67
Fair Value	20,333	2,933
Commercial Paper
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	52,182
Gross Unrealized Holding Gains	38
Gross Unrealized Holding Losses	0
Fair Value	52,220
U.S. Government Agency Securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	8,900	17,512
Gross Unrealized Holding Gains	1	5
Gross Unrealized Holding Losses	0	0
Fair Value	8,901	17,517
Greek Government-Issued Bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	51	48
Gross Unrealized Holding Gains	77	52
Gross Unrealized Holding Losses	0	0
Fair Value	$128	$100

Fair_Values_of_AvailableForSal

Fair Values of Available-For-Sale Securities by Contractual Maturity (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Maturing in one year or less	$198,086	$270,211
Maturing after one year through two years	147,771	115,993
Total	$345,857	$386,204

Changes_in_Goodwill_Detail

Changes in Goodwill (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Goodwill [Line Items]
Balance at December 31, 2012	$51,543	[1]
Addition of goodwill related to the acquisition of Zacharon	2,715
Balance at September 30, 2013	$54,258
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

Intangible_Assets_Detail

Intangible Assets (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Intangible assets:
Finite-lived intangible assets	$118,242	$118,242
Indefinite-lived intangible assets	74,430	63,689
Gross intangible assets	192,672	181,931
Less: Accumulated amortization	-26,881	-18,951
Net carrying value	$165,791	$162,980	[1]
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

Property_Plant_and_Equipment_D

Property Plant and Equipment (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Leasehold improvements	$67,083	$65,918
Building and improvements	154,479	144,700
Manufacturing and laboratory equipment	88,865	79,915
Computer hardware and software	63,164	56,011
Furniture and equipment	12,152	11,143
Land	11,608	11,608
Construction-in-progress	64,756	64,300
Property, Plant and Equipment, Gross, Total	462,107	433,595
Less: Accumulated depreciation	-176,443	-149,122
Total property, plant and equipment, net	$285,664	$284,473	[1]
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

Property_Plant_and_Equipment_A

Property Plant and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Line Items]
Depreciation expense	$9,200,000	$8,900,000	$27,300,000	$25,700,000
Depreciation expense capitalized into inventory	$2,800,000	$2,500,000	$8,221,000	$4,744,000

Schedule_of_Inventory_Detail

Schedule of Inventory (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Condensed Financial Statements, Captions [Line Items]
Raw materials	$15,350	$11,943
Work-in-process	80,996	71,443
Finished goods	52,338	45,309
Total inventory	$148,684	$128,695	[1]
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

Inventory_Additional_Informati

Inventory - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory [Line Items]
Inventory	$148,684	$128,695	[1]
Pending Regulatory Approvals
Inventory [Line Items]
Inventory	2,200	12,000
Pending Regulatory Approvals | Approval of Vimizim In US or EU
Inventory [Line Items]
Inventory	$32,700	$0
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

Schedule_of_Accounts_Payable_a

Schedule of Accounts Payable and Accrued Liabilities (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Condensed Financial Statements, Captions [Line Items]
Accounts payable	$15,632	$23,993
Accrued accounts payable	58,666	43,156
Accrued vacation expense	9,717	8,403
Accrued compensation expense	28,574	27,530
Accrued royalties payable	5,279	4,991
Accrued rebates payable	10,147	9,625
Other accrued operating expenses	1,891	6,179
Current portion of nonqualified deferred compensation liability	1,559	6,440
Value added taxes payable	4,240	2,072
Current portion of contingent acquisition consideration payable	26,536	10,764
Other	5,392	3,915
Total accounts payable and accrued liabilities	$167,633	$147,068	[1]
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

Recovered_Sheet3

Derivative Instruments and Hedging Strategies - Additional Information (Detail)	9 Months Ended	12 Months Ended	9 Months Ended				9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
	USD ($)	USD ($)	Maximum	Minimum	Derivatives Designated As Hedging Instruments	Derivatives Designated As Hedging Instruments	Derivatives Not Designated As Hedging Instruments	Derivatives Not Designated As Hedging Instruments
					Foreign Currency Derivatives	Euro		Foreign Currency Derivatives
					Sale Contracts			Sale Contracts
					EUR (€)			EUR (€)
Derivative [Line Items]
Number of forward foreign currency exchange contracts outstanding						58	1
Outstanding forward foreign currency exchange contracts					€ 57,100,000			€ 28,100,000
Maturity period of foreign currency derivatives			31-Dec-14	31-Oct-13			31-Oct-13
Amount reclassified from accumulated other comprehensive income to earnings as related to forecasted revenue transactions	2,000,000
Maximum length of time over which hedging its exposure to the reduction in value of forecasted foreign currency cash flows through foreign currency forward contracts			12 months
Gain (Loss) from foreign currency exchange contracts in accumulated other comprehensive income	($2,100,000)	($200,000)

Recovered_Sheet4

Derivative Instruments and Hedging Strategies (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Derivatives Designated As Hedging Instruments
Derivative [Line Items]
Derivative Asset, Fair Value	$0	$1,463
Derivative Liability, Fair Value	1,805	1,446
Derivatives Designated As Hedging Instruments | Forward Foreign Currency Exchange Contracts | Accounts Payable and Accrued Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value	1,674	1,078
Derivatives Designated As Hedging Instruments | Forward Foreign Currency Exchange Contracts | Other Long-Term Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value	131	368
Derivatives Designated As Hedging Instruments | Forward Foreign Currency Exchange Contracts | Other Current Assets
Derivative [Line Items]
Derivative Asset, Fair Value	0	1,463
Derivatives Designated As Hedging Instruments | Forward Foreign Currency Exchange Contracts | Other Assets
Derivative [Line Items]
Derivative Asset, Fair Value	0	0
Derivatives Not Designated As Hedging Instruments
Derivative [Line Items]
Derivative Asset, Fair Value	0	1,547
Derivative Liability, Fair Value	1,951	1,446
Derivatives Not Designated As Hedging Instruments | Forward Foreign Currency Exchange Contracts
Derivative [Line Items]
Derivative Asset, Fair Value	0	84
Derivative Liability, Fair Value	146	0
Derivatives Not Designated As Hedging Instruments | Forward Foreign Currency Exchange Contracts | Accounts Payable and Accrued Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value	146	0
Derivatives Not Designated As Hedging Instruments | Forward Foreign Currency Exchange Contracts | Other Current Assets
Derivative [Line Items]
Derivative Asset, Fair Value	$0	$84

Effect_of_Derivative_Instrumen

Effect of Derivative Instruments (Detail) (USD $)

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Forward Foreign Currency Exchange Contracts

Forward Foreign Currency Exchange Contracts

Forward Foreign Currency Exchange Contracts

Forward Foreign Currency Exchange Contracts

Forward Foreign Currency Exchange Contracts

Forward Foreign Currency Exchange Contracts

Forward Foreign Currency Exchange Contracts

Forward Foreign Currency Exchange Contracts

Derivatives Designated As Hedging Instruments

Derivatives Designated As Hedging Instruments

Derivatives Designated As Hedging Instruments

Derivatives Designated As Hedging Instruments

Derivatives Not Designated As Hedging Instruments

Derivatives Not Designated As Hedging Instruments

Derivatives Not Designated As Hedging Instruments

Derivatives Not Designated As Hedging Instruments

Derivative Instruments, Gain (Loss) [Line Items]

Net gain (loss) recognized in Other Comprehensive Income (OCI)

($2,100)

($200)

($3,177)

[1]

($3,952)

[1]

($1,918)

[1]

($4,612)

[1]

Net gain reclassified from accumulated OCI into income

102

[2]

2,362

[2]

968

[2]

4,916

[2]

Net gain (loss) recognized in income

$10

[3]

$218

[3]

$214

[3]

$753

[3]

($1,437)

[4]

($1,388)

[4]

($1,129)

[4]

$1,286

[4]

[1]

Net change in the fair value of the effective portion classified as OCI.

[2]

Effective portion classified as net product revenue.

[3]

Ineffective portion and amount excluded from effectiveness testing classified as selling, general and administrative expense

[4]

Classified as selling, general and administrative expense.

Convertible_Debt_Additional_In

Convertible Debt - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Apr. 30, 2007

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Aug. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2006

Mar. 31, 2013

Due 2017

Due 2017

Due 2017

Due 2017

Due 2017

Due 2017

Due 2017

Due 2017

Due 2017

Due 2017

Due 2017

Due 2017

Due 2017

Due 2013

Due 2013

Agreement One

Agreement One

Agreement One

Agreement Two

Agreement Two

Convertible Debt

Convertible Debt

Convertible Debt

Agreement One

Agreement One

Agreement Two

Debt Conversion [Line Items]

Debt instrument, face amount

$324,900,000

$172,500,000

Convertible debt

78,310,000

78,310,000

348,224,000

78,300,000

78,300,000

Debt instrument, interest rate, stated percentage, per annum

1.88%

2.50%

Debt instrument, convertible, conversion price, per share

$20.36

$16.58

Maturity date of convertible debt

23-Apr-17

29-Mar-13

Payments of debt issuance costs

8,500,000

Amortization expense

100,000

200,000

300,000

600,000

Convertible notes aggregate principal

31,500,000

215,000,000

23,300,000

Notes converted, number of shares

1,547,629

10,560,164

Convertible cash premium paid to holder for agreeing to convert

1,732,000

0

12,152,000

0

1,900,000

1,900,000

12,000,000

1,700,000

1,700,000

10,400,000

Interest expense on convertible debt

200,000

1,600,000

Reclassified of deferred offering costs to additional paid-in capital

300,000

2,300,000

Common stock issued upon conversion of convertible notes

1,403,735

Payment on debt conversion

12,152,000

0

98

Interest expense

$526,000

$1,837,000

$2,854,000

$5,709,000

$500,000

$1,700,000

$2,500,000

$5,000,000

Fixed_Rate_Convertible_Debt_Ou

Fixed Rate Convertible Debt Outstanding (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Fixed rate convertible debt on balance sheet	$78,310	$348,224
Fair value of fixed rate convertible debt	$280,387	$811,798

Fair_Value_of_Financial_Assets

Fair Value of Financial Assets and Liabilities (Detail) (USD $)	Sep. 30, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	$181,565		$180,527
Fair value of Available-for-sale securities	345,857		386,204
Total other current assets	2,577		5,842
Total other assets	4,839		5,867
Fair value of financial assets, Total	534,838		578,440
Nonqualified Deferred Compensation Plan liability	1,559		6,440
Asset retirement obligation			1,685
Total current liabilities	29,915		19,967
Contingent acquisition consideration payable	26,536		10,764
Total other long-term liabilities	46,463		42,646
Fair value of financial liabilities, Total	76,378		62,613
Corporate Equity Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	20,333		2,933
U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	8,901		17,517
Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	52,220
Overnight Deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	170,717		54,018
Money Market Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	10,848		126,509
Available-For-Sale Securities Short-Term | Corporate Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	94,472		222,147
Available-For-Sale Securities Short-Term | Corporate Equity Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	20,333		2,933
Available-For-Sale Securities Short-Term | U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities			8,516
Available-For-Sale Securities Short-Term | Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	52,220
Available-For-Sale Securities Short-Term | Certificates of Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	31,061		36,615
Available-For-Sale Securities Long-Term | Corporate Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	124,270		94,753
Available-For-Sale Securities Long-Term | U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	8,901		9,001
Available-For-Sale Securities Long-Term | Greek Government-Issued Bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	128		100
Available-For-Sale Securities Long-Term | Certificates of Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	14,472		12,139
Other Current Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	2,528	[1]	2,243	[1]
Other Current Assets | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan assets	49		2,052
Other Current Assets | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract asset			1,547	[2]
Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	1,489	[1]	3,492	[1]
Other Assets | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan assets	3,350		2,375
Current Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent acquisition consideration payable	26,536		10,764
Current Liabilities | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan liability	1,559		6,440
Current Liabilities | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract liability	1,820	[2]	1,078	[2]
Other Long-Term Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent acquisition consideration payable	26,500		30,618
Asset retirement obligation	4,014		2,192
Other Long-Term Liabilities | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan liability	15,818		9,468
Other Long-Term Liabilities | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract liability	131	[2]	368	[2]
Quoted Price In Active Markets For Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	170,717		54,018
Fair value of Available-for-sale securities	0		0
Total other current assets	0		0
Total other assets	0		0
Fair value of financial assets, Total	170,171		54,018
Asset retirement obligation			0
Total current liabilities	1,510		6,440
Total other long-term liabilities	12,468		5,041
Fair value of financial liabilities, Total	13,978		11,481
Quoted Price In Active Markets For Identical Assets (Level 1) | Overnight Deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	170,717		54,018
Quoted Price In Active Markets For Identical Assets (Level 1) | Money Market Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Available-For-Sale Securities Short-Term | Corporate Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Available-For-Sale Securities Short-Term | Corporate Equity Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Available-For-Sale Securities Short-Term | U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities			0
Quoted Price In Active Markets For Identical Assets (Level 1) | Available-For-Sale Securities Short-Term | Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0
Quoted Price In Active Markets For Identical Assets (Level 1) | Available-For-Sale Securities Short-Term | Certificates of Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Available-For-Sale Securities Long-Term | Corporate Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Available-For-Sale Securities Long-Term | U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Available-For-Sale Securities Long-Term | Greek Government-Issued Bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Available-For-Sale Securities Long-Term | Certificates of Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Other Current Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	0	[1]	0	[1]
Quoted Price In Active Markets For Identical Assets (Level 1) | Other Current Assets | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan assets	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Other Current Assets | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract asset			0	[2]
Quoted Price In Active Markets For Identical Assets (Level 1) | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	0	[1]	0	[1]
Quoted Price In Active Markets For Identical Assets (Level 1) | Other Assets | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan assets	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Current Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent acquisition consideration payable	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Current Liabilities | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan liability	1,510		6,440
Quoted Price In Active Markets For Identical Assets (Level 1) | Current Liabilities | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract liability	0	[2]	0	[2]
Quoted Price In Active Markets For Identical Assets (Level 1) | Other Long-Term Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent acquisition consideration payable	0		0
Asset retirement obligation	0		0
Quoted Price In Active Markets For Identical Assets (Level 1) | Other Long-Term Liabilities | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan liability	12,468		5,041
Quoted Price In Active Markets For Identical Assets (Level 1) | Other Long-Term Liabilities | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract liability	0	[2]	0	[2]
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	10,848		126,509
Fair value of Available-for-sale securities	345,857		386,204
Total other current assets	2,577		5,842
Total other assets	4,839		5,867
Fair value of financial assets, Total	364,121		524,422
Asset retirement obligation			0
Total current liabilities	1,869		1,078
Total other long-term liabilities	3,481		4,795
Fair value of financial liabilities, Total	5,350		5,873
Significant Other Observable Inputs (Level 2) | Overnight Deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	0		0
Significant Other Observable Inputs (Level 2) | Money Market Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	10,848		126,509
Significant Other Observable Inputs (Level 2) | Available-For-Sale Securities Short-Term | Corporate Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	94,472		222,147
Significant Other Observable Inputs (Level 2) | Available-For-Sale Securities Short-Term | Corporate Equity Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	20,333		2,933
Significant Other Observable Inputs (Level 2) | Available-For-Sale Securities Short-Term | U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities			8,516
Significant Other Observable Inputs (Level 2) | Available-For-Sale Securities Short-Term | Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	52,220
Significant Other Observable Inputs (Level 2) | Available-For-Sale Securities Short-Term | Certificates of Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	31,061		36,615
Significant Other Observable Inputs (Level 2) | Available-For-Sale Securities Long-Term | Corporate Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	124,270		94,753
Significant Other Observable Inputs (Level 2) | Available-For-Sale Securities Long-Term | U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	8,901		9,001
Significant Other Observable Inputs (Level 2) | Available-For-Sale Securities Long-Term | Greek Government-Issued Bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	128		100
Significant Other Observable Inputs (Level 2) | Available-For-Sale Securities Long-Term | Certificates of Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	14,472		12,139
Significant Other Observable Inputs (Level 2) | Other Current Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	2,528	[1]	2,243	[1]
Significant Other Observable Inputs (Level 2) | Other Current Assets | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan assets	49		2,052
Significant Other Observable Inputs (Level 2) | Other Current Assets | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract asset			1,547	[2]
Significant Other Observable Inputs (Level 2) | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	1,489	[1]	3,492	[1]
Significant Other Observable Inputs (Level 2) | Other Assets | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan assets	3,350		2,375
Significant Other Observable Inputs (Level 2) | Current Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent acquisition consideration payable	0		0
Significant Other Observable Inputs (Level 2) | Current Liabilities | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan liability	49		0
Significant Other Observable Inputs (Level 2) | Current Liabilities | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract liability	1,820	[2]	1,078	[2]
Significant Other Observable Inputs (Level 2) | Other Long-Term Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent acquisition consideration payable	0		0
Asset retirement obligation	0		0
Significant Other Observable Inputs (Level 2) | Other Long-Term Liabilities | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan liability	3,350		4,427
Significant Other Observable Inputs (Level 2) | Other Long-Term Liabilities | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract liability	131	[2]	368	[2]
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	0		0
Fair value of Available-for-sale securities	0		0
Total other current assets	0		0
Total other assets	0		0
Fair value of financial assets, Total	0		0
Asset retirement obligation			1,685
Total current liabilities	26,536		12,449
Total other long-term liabilities	30,514		32,810
Fair value of financial liabilities, Total	57,050		45,259
Significant Unobservable Inputs (Level 3) | Overnight Deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	0		0
Significant Unobservable Inputs (Level 3) | Money Market Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Cash and cash equivalents	0		0
Significant Unobservable Inputs (Level 3) | Available-For-Sale Securities Short-Term | Corporate Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Significant Unobservable Inputs (Level 3) | Available-For-Sale Securities Short-Term | Corporate Equity Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Significant Unobservable Inputs (Level 3) | Available-For-Sale Securities Short-Term | U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities			0
Significant Unobservable Inputs (Level 3) | Available-For-Sale Securities Short-Term | Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0
Significant Unobservable Inputs (Level 3) | Available-For-Sale Securities Short-Term | Certificates of Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Significant Unobservable Inputs (Level 3) | Available-For-Sale Securities Long-Term | Corporate Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Significant Unobservable Inputs (Level 3) | Available-For-Sale Securities Long-Term | U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Significant Unobservable Inputs (Level 3) | Available-For-Sale Securities Long-Term | Greek Government-Issued Bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Significant Unobservable Inputs (Level 3) | Available-For-Sale Securities Long-Term | Certificates of Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Available-for-sale securities	0		0
Significant Unobservable Inputs (Level 3) | Other Current Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	0	[1]	0	[1]
Significant Unobservable Inputs (Level 3) | Other Current Assets | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan assets	0		0
Significant Unobservable Inputs (Level 3) | Other Current Assets | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract asset			0	[2]
Significant Unobservable Inputs (Level 3) | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted investments	0	[1]	0	[1]
Significant Unobservable Inputs (Level 3) | Other Assets | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan assets	0		0
Significant Unobservable Inputs (Level 3) | Current Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent acquisition consideration payable	26,536		10,764
Significant Unobservable Inputs (Level 3) | Current Liabilities | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan liability	0		0
Significant Unobservable Inputs (Level 3) | Current Liabilities | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract liability	0	[2]	0	[2]
Significant Unobservable Inputs (Level 3) | Other Long-Term Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent acquisition consideration payable	26,500		30,618
Asset retirement obligation	4,014		2,192
Significant Unobservable Inputs (Level 3) | Other Long-Term Liabilities | Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Nonqualified Deferred Compensation Plan liability	0		0
Significant Unobservable Inputs (Level 3) | Other Long-Term Liabilities | Foreign Exchange Forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward foreign currency exchange contract liability	$0	[2]	$0	[2]
[1]	The restricted investments secure the Company's irrevocable standby letter of credit obtained in connection with the Company's new corporate facility lease agreements and certain commercial agreements.
[2]	See Note 12 to these Condensed Consolidated Financial Statements for further information regarding the derivative instruments.

Liabilities_Measured_at_Fair_V

Liabilities Measured at Fair Value Using Level 3 Inputs (Detail) (Contingent Payment, USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Contingent Payment
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent acquisition consideration payable at December 31, 2012	$41,382
Changes in the fair value of the contingent acquisition consideration payable	9,816
Addition of contingent consideration payable related to the Zacharon acquisition	1,857
Milestone payment to former LEAD shareholders	-19
Contingent acquisition consideration payable at September 30, 2013	$53,036

Fair_Value_Measurement_Additio

Fair Value Measurement - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset retirement obligations	$4	$3.90

Stock_Based_Compensation_Addit

Stock Based Compensation - Additional Information (Detail) (USD $)	9 Months Ended						9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	8-May-12	Sep. 30, 2013
			Maximum	Minimum	Restricted Stock Units (RSUs)	2012 Inducement Plan	Share Incentive Plan
						Maximum	Performance Awards
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Share based awards, authorized						750,000
Options, Granted	2,403,722
Weighted Average fair value, Granted	$30.62
Shares, Granted					558,231
Weighted Average fair value, Granted					$66.74		$34.66
Granted restricted stock units							860,000
Total shareholder return, percentage of multiplier range			125.00%	75.00%
Stock-based compensation capitalized to inventory	$4.20	$3

Assumptions_Used_to_Estimate_P

Assumptions Used to Estimate Per Share Fair Value of Stock Options Granted (Detail) (Stock Option)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	44.00%	46.00%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected life	6 years 9 months 18 days	6 years 6 months		6 years 6 months
Risk-free interest rate	2.20%	0.90%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility			44.00%	45.00%
Expected life			6 years 7 months 6 days
Risk-free interest rate			1.00%	0.80%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility			45.00%	46.00%
Expected life			6 years 9 months 18 days
Risk-free interest rate			2.40%	1.10%

Compensation_Expense_Detail

Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$16,205	$12,139	$41,698	$35,907
Cost of Sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,489	1,327	3,663	3,535
Research and Development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	7,116	5,060	18,821	15,351
Selling, General And Administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$7,600	$5,752	$19,214	$17,021

AntiDilutive_Common_Stock_Excl

Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive	18,986	35,161	18,923	35,111
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive	13,421	15,998	13,421	15,998
Common stock issuable under convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive	3,846	17,370	3,846	17,370
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive	1,235	1,297	1,180	1,256
Potentially issuable common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive	290	263	282	254
Common stock held by the Nonqualified Deferred Compensation Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock excluded from computation of earnings (loss) per share as they are anti-dilutive	194	233	194	233

Amounts_Reclassified_out_of_Ac

Amounts Reclassified out of Accumulated Other Comprehensive Income or Loss (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net product revenues	$134,330	$126,310	$394,074	$365,540
Selling, general and administrative	-61,841	-46,337	-163,547	-143,124
Income tax expense	-704	6,404	2,765	6,849
NET LOSS	-53,020	-5,357	-114,363	-61,335
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Foreign Exchange Contract | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net product revenues	-101		-928
Selling, general and administrative	0		-40
Income tax expense	36		349
NET LOSS	($65)		($619)

Summary_of_Changes_in_Accumula

Summary of Changes in Accumulated Balances of Other Comprehensive Income Loss Including Current Period Other Comprehensive Income and Reclassifications (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	($202)	[1]
Other comprehensive income before reclassifications	12,294
Amounts reclassified from AOCI	-619
Net increase in other comprehensive income (loss)	11,675
Ending Balance	11,473
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	-97
Other comprehensive income before reclassifications	-606
Amounts reclassified from AOCI	-619
Net increase in other comprehensive income (loss)	-1,225
Ending Balance	-1,322
Unrealized Gain/(Losses) on Available-for-sale-Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	133
Other comprehensive income before reclassifications	11,007
Amounts reclassified from AOCI	0
Net increase in other comprehensive income (loss)	11,007
Ending Balance	11,140
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	-238
Other comprehensive income before reclassifications	1,893
Amounts reclassified from AOCI	0
Net increase in other comprehensive income (loss)	1,893
Ending Balance	$1,655
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

Recovered_Sheet5

Revenue and Credit Concentrations - Additional Information (Detail) (USD $)

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Customer

Southern European Countries

Southern European Countries

Southern European Countries

Southern European Countries

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Customer Concentration Risk

Net Product Revenues

Net Product Revenues

Accounts Receivable

Accounts Receivable

Net Product Revenues

Net Product Revenues

Net Product Revenues

Net Product Revenues

Net Product Revenues

Net Product Revenues

Net Product Revenues

Net Product Revenues

Net Product Revenues

Net Product Revenues

Net Product Revenues

Net Product Revenues

Accounts Receivable

Accounts Receivable

Accounts Receivable

Accounts Receivable

Customer A

Customer A

Customer A

Customer A

Customer B

Customer B

Customer B

Customer B

Customer A

Customer A

Customer B

Customer B

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue concentration risk

10.00%

Number of customers accounted for largest balance in accounts receivable

2

Concentration risk, percentage

4.00%

4.00%

12.00%

12.00%

47.00%

52.00%

49.00%

51.00%

15.00%

14.00%

15.00%

15.00%

17.00%

[1]

18.00%

[1]

15.00%

[1]

15.00%

[1]

39.00%

51.00%

13.00%

13.00%

Accounts receivable, net

$124,745

$109,066

[2]

$28,200

$32,400

[1]

Genzyme is the Company's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third-parties. Net product revenues from Genzyme are comprised of royalties on worldwide net Aldurazyme sales and incremental product transfer revenue.

[2]

December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

Consolidated_Net_Product_Reven

Consolidated Net Product Revenue Attributed to Largest Customers (Detail) (Net Product Revenues)	3 Months Ended				9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Geographic Concentration Risk
Segment Reporting, Revenue Reconciling Item [Line Items]
Concentration risk, percentage	100.00%		100.00%		100.00%		100.00%
Geographic Concentration Risk | United States
Segment Reporting, Revenue Reconciling Item [Line Items]
Concentration risk, percentage	54.00%		53.00%		51.00%		50.00%
Geographic Concentration Risk | Europe
Segment Reporting, Revenue Reconciling Item [Line Items]
Concentration risk, percentage	21.00%		21.00%		21.00%		22.00%
Geographic Concentration Risk | Latin America
Segment Reporting, Revenue Reconciling Item [Line Items]
Concentration risk, percentage	8.00%		14.00%		12.00%		15.00%
Geographic Concentration Risk | Rest of World
Segment Reporting, Revenue Reconciling Item [Line Items]
Concentration risk, percentage	17.00%		12.00%		16.00%		13.00%
Customer Concentration Risk
Segment Reporting, Revenue Reconciling Item [Line Items]
Concentration risk, percentage	47.00%		52.00%		49.00%		51.00%
Customer Concentration Risk | Customer A
Segment Reporting, Revenue Reconciling Item [Line Items]
Concentration risk, percentage	15.00%		14.00%		15.00%		15.00%
Customer Concentration Risk | Customer B
Segment Reporting, Revenue Reconciling Item [Line Items]
Concentration risk, percentage	17.00%	[1]	18.00%	[1]	15.00%	[1]	15.00%	[1]
Customer Concentration Risk | Customer C
Segment Reporting, Revenue Reconciling Item [Line Items]
Concentration risk, percentage	4.00%		11.00%		8.00%		12.00%
Customer Concentration Risk | Customer D
Segment Reporting, Revenue Reconciling Item [Line Items]
Concentration risk, percentage	11.00%		9.00%		11.00%		9.00%
[1]	Genzyme is the Company's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third-parties. Net product revenues from Genzyme are comprised of royalties on worldwide net Aldurazyme sales and incremental product transfer revenue.

Schedule_of_Accounts_Receivabl

Schedule of Accounts Receivable by Country that were Past Due (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts Receivable [Line Items]
Total Amount Past Due	$5,229
Allowance for Doubtful Accounts	376	348	[1]
ITALY
Accounts Receivable [Line Items]
Total Amount Past Due	0
SPAIN
Accounts Receivable [Line Items]
Total Amount Past Due	4,603
PORTUGAL
Accounts Receivable [Line Items]
Total Amount Past Due	267
GREECE
Accounts Receivable [Line Items]
Total Amount Past Due	359
Less Than 180 Days
Accounts Receivable [Line Items]
Total Amount Past Due	2,187
Less Than 180 Days | ITALY
Accounts Receivable [Line Items]
Total Amount Past Due	0
Less Than 180 Days | SPAIN
Accounts Receivable [Line Items]
Total Amount Past Due	1,920
Less Than 180 Days | PORTUGAL
Accounts Receivable [Line Items]
Total Amount Past Due	267
Less Than 180 Days | GREECE
Accounts Receivable [Line Items]
Total Amount Past Due	0
180 -360 Days
Accounts Receivable [Line Items]
Total Amount Past Due	1,467
180 -360 Days | ITALY
Accounts Receivable [Line Items]
Total Amount Past Due	0
180 -360 Days | SPAIN
Accounts Receivable [Line Items]
Total Amount Past Due	1,467
180 -360 Days | PORTUGAL
Accounts Receivable [Line Items]
Total Amount Past Due	0
180 -360 Days | GREECE
Accounts Receivable [Line Items]
Total Amount Past Due	0
Greater Than 360 Days
Accounts Receivable [Line Items]
Total Amount Past Due	1,575
Greater Than 360 Days | ITALY
Accounts Receivable [Line Items]
Total Amount Past Due	0
Greater Than 360 Days | SPAIN
Accounts Receivable [Line Items]
Total Amount Past Due	1,216
Greater Than 360 Days | PORTUGAL
Accounts Receivable [Line Items]
Total Amount Past Due	0
Greater Than 360 Days | GREECE
Accounts Receivable [Line Items]
Total Amount Past Due	359
Foreign Operations
Accounts Receivable [Line Items]
Allowance for Doubtful Accounts	359
Foreign Operations | ITALY
Accounts Receivable [Line Items]
Allowance for Doubtful Accounts	0
Foreign Operations | SPAIN
Accounts Receivable [Line Items]
Allowance for Doubtful Accounts	0
Foreign Operations | PORTUGAL
Accounts Receivable [Line Items]
Allowance for Doubtful Accounts	0
Foreign Operations | GREECE
Accounts Receivable [Line Items]
Allowance for Doubtful Accounts	$359
[1]	December 31, 2012 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the SEC) on February 26, 2013.

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Commitments and Contingencies [Line Items]
Contingent payments upon achievement of certain regulatory and licensing milestones	$438.40
Completed Programs
Commitments and Contingencies [Line Items]
Contingent payments upon achievement of certain regulatory and licensing milestones	$57.60

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (Subsequent Event, USD $)	1 Months Ended
	Oct. 15, 2013
Subsequent Event [Line Items]
Debt instrument, face amount	$750,000,000
Net proceeds from offering debt	726,400,000
Debt instrument, frequency of interest payment	Payable semiannually in arrears on April 15 and October 15 of each year beginning on April 15, 2014
Debt instrument, convertible, conversion rate	10.6213
Debt instrument, convertible, principal amount	1,000
Debt instrument, convertible, conversion price	$94.15
Capped call transactions
Subsequent Event [Line Items]
Payment for privately-negotiated capped Call transactions	29,800,000
Capped call transactions, cap price	121.05
Due 2018
Subsequent Event [Line Items]
Debt instrument, face amount	375,000,000
Debt instrument, interest rate, stated percentage, per annum	0.75%
Maturity date of convertible debt	2018-10
Due 2020
Subsequent Event [Line Items]
Debt instrument, face amount	$375,000,000
Debt instrument, interest rate, stated percentage, per annum	1.50%
Maturity date of convertible debt	2020-10
Due 2020 | Capped call transactions
Subsequent Event [Line Items]
Percentage of the principal amount	50.00%
Senior Notes Due Two Thousand Eighteen | Capped call transactions
Subsequent Event [Line Items]
Percentage of the principal amount	50.00%